2-benzyloxy-4-phenoxypyrimidine derivative, processes for producing the derivative and herbicidal composition containing the derivative

BACKGROUND OF THE INVENTION
The present invention relates to a novel 2-benzyloxy-4-phenoxypyrimidine derivative, processes for producing the derivative and a herbicidal composition containing the derivative as an active ingredient.
Compounds which have the structural formulae partly common with those of the present invention are known as cited in the following.
Among 2-benzyloxypyrimidine derivatives, three compounds, namely, 2-benzyloxypyrimidine, 2-benzyloxy-4-ethoxypyrimidine, and 2-benzyloxy-4,6-dimethylpyrimidine are described respectively in the following publications: 2-benzyloxypyrimidine: J. Chem. Soc., 1965, 5542-5549; 2-benzyloxy-4-ethoxypyrimidine: J. Chem. Soc., Perkin Trans. 1, 1975, 1798-1802; and 2-benzyloxy-4,6-dimethylpyrimidine: J. Chem. Soc., 1959, 525-530.
However, these publications have suggested nothing about herbicidal activity thereof.
On the other hand, phenoxypyrimidine derivatives and herbicidal activity thereof have been described in Agri. Biol. Chem., 30, 896-905 (1966).
The present inventors have established a process for the preparation of a novel 2-benzyloxy-4-phenoxypyrimidine derivative and also have found that the compound has herbicidal properties, and thus attained the present invention.
SUMMARY OF THE INVENTION
In a first aspect of the present invention, there is provided a 2-benzyloxy-4-phenoxypyrimidine derivative represented by the formula (I): ##STR2## wherein R.sup.1 represents hydrogen, a halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 haloalkoxy, C.sub.3 -C.sub.5 alkenyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 haloalkylthio, cyano, or phenyl;
each X, which may be identical or different if n is greater than 1, represents a halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, or C.sub.1 -C.sub.4 alkoxy;
each Y, which may be identical or different if m is greater than 1, represents a halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 haloalkoxy, C.sub.1 -C.sub.4 alkylthio, or C.sub.1 -C.sub.4 haloalkylthio; and
n and m each independently represent an integer of 0 to 5.
In a second aspect of the present invention, there is provided a process for producing a 2-benzyloxy-4-phenoxypyrimidine derivative of the formula (I): ##STR3## wherein R.sup.1, X, Y, m, and n are as defined above, which comprises reacting a 2-benzyloxy-4 (or 6)-halogeno (or 4,6-dihalogeno) pyrimidine derivative of the formula (II): ##STR4## wherein R.sup.1, X, and n are as defined above and R.sup.2 represents a halogen, with a phenol compound of the formula (III): ##STR5## wherein Y and m are as defined above, in the presence of a basic compound.
In a third aspect of the present invention, there is provided a process for producing a 2-benzyloxy-4-phenoxypyrimidine derivative of the formula (I-a): ##STR6## wherein R.sup.1 a represents hydrogen, a halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 haloalkoxy, C.sub.3 -C.sub.5 alkenyloxy, cyano, or phenyl;
each X, which may be identical or different if n is greater than 1, represents a halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, or C.sub.1 -C.sub.4 alkoxy;
each Ya, which may be identical or different if m is greater than 1, represents a halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.4 alkoxy, or C.sub.1 -C.sub.4 haloalkoxy; and
n and m each independently represent an integer of 0 to 5, which comprises reacting a 2-(substituted sulfonyl)-4-phenoxypyrimidine derivative of the formula (V): ##STR7## wherein R.sup.1 a, Ya and m are as defined above and R.sup.3 represents C.sub.1 -C.sub.4 alkyl, C.sub.7 -C.sub.9 aralkyl, or aryl, with a benzyl alcohol compound of the formula (IV): ##STR8## wherein X and n are as defined above, in the presence of a basic compound.
In a fourth aspect of the present invention, there is provided a herbicidal composition comprising a 2-benzyloxy-4-phenoxypyrimidine derivative represented by the formula (I): ##STR9## wherein R.sup.1, X, Y, m, and n are as defined above, and an adjuvant.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the terms "haloalkyl", "haloalkoxy" and "haloalkylthio" respectively mean alkyl, alkoxy and alkylthio in which at least one hydrogen is substituted with a halogen.
Atomic symbols, abbreviations, and rational formulae given in parentheses are employed in the tables giving examples of the compounds of the present invention: Table 1 (1/34 to 34/34), Table 2 (1/5 to 5/5), Table 3, Table 4, and Table 5 (1/12 to 12/12).
R.sup.1 and R.sup.1 a each independently include the following atoms and substituents:
hydrogen (H);
a halogen such as chlorine (Cl), bromine (Br), and iodine (I);
C.sub.3 -C.sub.5 alkenyloxy such as allyloxy (OCH.sub.2 CH.dbd.CH.sub.2), (2-methyl-2-propenyl)oxy, crotyloxy, (3-methyl-2-butenyl)oxy (OCH.sub.2 CH.dbd.CMe.sub.2), and (3-methyl-3-butenyl)oxy;
C.sub.1 -C.sub.4 alkyl such as methyl (Me), ethyl (Et), 1-methylethyl, 1,1-dimethylethyl (t-Bu), propyl, and butyl;
C.sub.1 -C.sub.4 alkoxy such as methoxy (OMe), ethoxy (OEt), (1-methylethyl)oxy (0-i-Pr), propoxy (OPr), (2-methylpropyl)oxy, (1-methylpropyl)oxy, and butoxy (OBu);
C.sub.1 -C.sub.4 alkylthio such as methylthio (SMe) and ethylthio (SEt);
C.sub.1 -C.sub.4 haloalkyl such as trifluoromethyl (CF.sub.3), fluoromethyl, difluoromethyl, and 2,2,2-trifluoroethyl;
C.sub.1 -C.sub.4 haloalkoxy such as difluoromethoxy, 1,1,2,2-tetrafluoroethoxy, 2,2,2-trifluoroethoxy (OCH.sub.2 CF.sub.3), 2-fluoroethoxy, 2-bromo-1,1,2-trifluoroethoxy, 2,2,3,3,3-pentafluoropropoxy, 1,1,2,3,3,3-hexafluoropropoxy, and 2-chloro-1,1,2-trifluoroethoxy;
C.sub.1 -C.sub.4 haloalkylthio such as (2,2,2-trifluoroethyl)thio (SCH.sub.2 CF.sub.3);
cyano (CN); and
phenyl (Ph).
Preferably, R.sup.1 represents hydrogen, a halogen (more preferably chlorine), methyl, methoxy, methylthio, or cyano.
Preferably, R.sup.1 a represents hydrogen, a halogen (more preferably chlorine), methyl, methoxy, or cyano.
R.sup.2 represents a halogen, preferably chlorine or bromine.
X includes the following atoms and groups:
a halogen such as fluorine (F), chlorine (Cl), bromine (Br), and iodine (I);
C.sub.1 -C.sub.4 alkyl such as methyl (Me), ethyl, 1-methylethyl, and butyl;
C.sub.1 -C.sub.4 alkoxy such as methoxy (OMe), ethoxy, (1-methylethyl)oxy, and (1-methylpropyl)oxy; and
C.sub.1 -C.sub.4 haloalkyl such as trifluoromethyl (CF.sub.3), fluoromethyl, difluoromethyl, and 2,2,2-trifluoroethyl.
Preferably, X represents a halogen (more preferably fluorine or chlorine), methyl, methoxy, or trifluoromethyl.
More preferably, X or each of two Xs is a halogen (still more preferably fluorine or chlorine) or methyl which is bonded to the position 3 or 4.
Y and Ya each independently include the following atoms and groups:
a halogen such as fluorine (F), chlorine (Cl), bromine (Br), and iodine (I);
C.sub.1 -C.sub.4 alkyl such as methyl (Me), ethyl, 1-methylethyl, and butyl;
C.sub.1 -C.sub.4 alkoxy such as methoxy (OMe), ethoxy, (1-methylethyl)oxy, and (1-methylpropyl)oxy;
C.sub.1 -C.sub.4 alkylthio such as methylthio (SMe) and ethylthio;
C.sub.1 -C.sub.4 haloalkyl such as trifluoromethyl (CF.sub.3), fluoromethyl, difluoromethyl, and 2,2,2-trifluoroethyl;
C.sub.1 -C.sub.4 haloalkoxy such as difluoromethoxy, trifluoromethoxy (OCF.sub.3), 1,1,2,2-tetrafluoroethoxy, 2,2,2-trifluoroethoxy, 2-fluoroethoxy, 2-bromo-1,1,2-trifluoroethoxy, 2,2,3,3,3-pentafluoropropoxy, 1,1,2,3,3,3-hexafluoropropoxy, and 2-chloro-1,1,2-trifluoroethoxy; and
C.sub.1 -C.sub.4 haloalkylthio such as trifluoromethylthio (SCF.sub.3) and (2,2,2-trifluoroethyl)thio (SCH.sub.2 CF.sub.3).
Preferably, Y represents a halogen (more preferably fluorine or chlorine), methyl, trifluoromethyl, trifluoromethoxy, or trifluoromethylthio.
Preferably, Ya represents a halogen (more preferably fluorine or chlorine), methyl, trifluoromethyl, or trifluoromethoxy.
More preferably, Y represents a halogen (still more preferably fluorine or chlorine), methyl, trifluoromethyl, trifluoromethoxy, or trifluoromethylthio which is bonded to the position 3.
More preferably, Ya represents a halogen (still more preferably fluorine or chlorine), methyl, trifluoromethyl, or trifluoromethoxy which is bonded to the position 3.
m represents an integer of 0 to 5, preferably 0 to 3, more preferably 0 or 1.
n represents an integer of 0 to 5, preferably 0 to 3, more preferably 0, 1 or 2.
If n is greater than 1, each X may be identical or different. If m is greater than 1, each Y and each Ya may be identical or different.
In the tables showing examples of the compounds, the positions bonded by atoms and substituents in the benzene ring are represented by figures and the symbol "--". For example, a methyl group bonded to the position 3 of the benzene ring is represented by 3-Me and two chlorine atoms respectively bonded to the position 2 and 4 are represented by 2,4-Cl.sub.2. When n or m represents 0, "H" is shown.
More preferably, each substituent in the derivative of the formula (I) represents the following:
X or Xs bond to the position 3 and/or 4, and represent a halogen (still more preferably fluorine or chlorine) or methyl.
Y bonds to the position 3, and represents a halogen (still more preferably fluorine or chlorine), methyl, trifluoromethyl, trifluoromethoxy, or trifluoromethylthio.
R.sup.1 represents hydrogen, a halogen (still more preferably fluorine or chlorine), methyl, methoxy, methylthio, or cyano.
R.sup.3 includes the following groups:
C.sub.1 -C.sub.4 alkyl such as methyl (Me) or ethyl;
C.sub.7 -C.sub.9 aralkyl such as benzyl; and
aryl (usually C.sub.6 -C.sub.7) such as phenyl or p-tolyl.
According to the present invention, a solvent is used generally for the production of the derivative represented by the formula (I). Examples of the solvent are set forth below:
water;
organic acids such as formic acid, acetic acid, and propionic acid;
aromatic hydrocarbons such as benzene, toluene, xylene, and methylnaphthalene;
aliphatic hydrocarbons such as petroleum ether, pentane, hexane, heptane, and methylcyclohexane;
halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, and chlorobenzene;
alcohols such as methanol, ethanol, i-propanol, and t-butanol;
amides such as dimethylformamide, dimethylacetamide, and N-methyl-2-pyrrolidinone;
ethers such as diethyl ether, dimethoxyethane, diisopropyl ether, tetrahydrofuran, diglyme, and dioxane;
ketones such as acetone and methyl ethyl ketone; as well as others including carbon disulfide, acetonitrile, ethyl acetate, pyridine, dimethyl sulfoxide, hexamethylphosphoric amide, and the like.
When the process of the present invention is carried out in the presence of a solvent, the above solvent may be used alone or in combination of two or more. When the combination of the solvents incapable of forming a homogeneous phase is used, the reaction may suitably be conducted in the presence of a phase transfer catalyst such as a conventional quaternary ammonium salt or a crown ether.
Examples of the basic compounds which is used in the process of the present invention are as follows:
alkaline metal carbonates such as sodium carbonate and potassium carbonate;
alkaline earth metal carbonates such as magnesium carbonate, calcium carbonate, and barium carbonate;
alkaline metal hydroxides such as sodium hydroxide and potassium hydroxide;
alkaline earth metal hydroxides such as magnesium hydroxide and calcium hydroxide;
alkaline earth metal oxides such as magnesium oxide and calcium oxide;
alkaline metals such as lithium, sodium and potassium as well as alkaline earth metals such as magnesium;
alkaline metal alkoxides such as sodium methoxide, sodium ethoxide, and potassium t-butoxide;
alkaline metal hydrides such as sodium hydride and potassium hydride;
alkaline earth metal hydrides such as calcium hydride;
organic alkaline metal compounds such as methyl lithium, ethyl lithium, n-butyl lithium and phenyl lithium;
Grignard reagents such as methylmagnesium iodide, ethylmagnesium bromide, and n-butylmagnesium bromide;
organic copper compounds prepared from organic alkaline metal compounds or Grignard reagents and copper(I) salts;
alkaline metal amides such as lithium diisopropylamide;
ammonium hydroxides having a nitrogen atom optionally substituted with an alkyl group or an aralkyl group, such as aqueous ammonia, benzyl trimethyl ammonium hydroxide and tetramethyl ammonium hydroxide; and
organic amines such as methylamine, ethylamine, n-propylamine, benzylamine, ethanolamine, dimethylamine, benzylmethylamine, dibenzylamine, triethylamine, triethanolamine, and pyridine.
If necessary, in the process of the present invention, an acidic compound may be used for post-treatment, for example. Examples of the acidic compound are as follows: inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, perchloric acid, and sulfuric acid; organic acids such as formic acid, acetic acid, butyric acid, and p-toluenesulfonic acid; and Lewis acids such as boron trifluoride, aluminium chloride, and zinc chloride.
Examples of the phenol compound represented by the formula (III) are as follows: phenol, 2-methylphenol, 2-methoxyphenol, 2-(trifluoromethyl)phenol, 2-bromophenol, 2-chlorophenol, 2-fluorophenol, 3-methylphenol, 3-methoxyphenol, 3-(methylthio)phenol, 3-(trifluoromethyl)phenol, 3-(trifluoromethoxy)phenol, 3-(trifluoromethylthio)phenol, 3-bromophenol, 3-chlorophenol, 3-fluorophenol, 3-iodophenol, 4-methylphenol, 4-methoxyphenol, 4-(methylthio)phenol, 4-(trifluoromethyl)phenol, 4-(trifluoromethoxy)phenol, 4-(trifluoromethylthio)phenol, 4-(2,2,2-trifluoroethylthio)phenol, 4-bromophenol, 4-chlorophenol, 4-fluorophenol, and 4-iodophenol.
Examples of the benzyl alcohol compound represented by the formula (IV) are as follows: benzyl alcohol, 2-methylbenzyl alcohol, 2-methoxybenzyl alcohol, 2-bromobenzyl alcohol, 2-chlorobenzyl alcohol, 2-fluorobenzyl alcohol, 3-methylbenzyl alcohol, 3-methoxybenzyl alcohol, 3-(trifluoromethyl)benzyl alcohol, 3-bromobenzyl alcohol, 3-chlorobenzyl alcohol, 3-fluorobenzyl alcohol, 3-iodobenzyl alcohol, 4-methylbenzyl alcohol, 4-methoxybenzyl alcohol, 4-(trifluoromethyl)benzyl alcohol, 4-bromobenzyl alcohol, 4-chlorobenzyl alcohol, 4-fluorobenzyl alcohol, 2,4-dimethoxybenzyl alcohol, 2,4-dichlorobenzyl alcohol, 2,4-difluorobenzyl alcohol, 3,4-dimethylbenzyl alcohol, 3,4-dichlorobenzyl alcohol, and 3,4-difluorobenzyl alcohol.
Examples of 2-benzyloxy-4-phenoxypyrimidine derivatives represented by the formula (I) are shown in Table 1 (1/34 to 34/34).
TABLE 1______________________________________No. X.sub.n Y.sub.m R.sup.1______________________________________I-1 H for H for HI-2 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-3 No. I-1 No. I-1 OCH.sub.2 CH.dbd.CMe.sub.2I-4 through through MeI-5 Compound Compound EtI-6 No. I-.27 No. I-27 t-BuI-7 OMeI-11 OEtI-12 OPrI-13 O-i-PrI-14 OBuI-15 SMeI-16 SEtI-17 PhI-21 CNI-22 CF.sub.3I-23 OCH.sub.2 CF.sub.3I-24 SCH.sub.2 CF.sub.3I-25 BrI-26 ClI-27 II-31 H for 2-Me for HI-32 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-33 No. I-31 No. I-31 OCH.sub.2 CH.dbd.CMe.sub.2I-34 through through MeI-35 Compound Compound EtI-36 No. I-57 No. I-57 t-BuI-37 OMeI-41 OEtI-42 OPrI-43 O-i-PrI-44 OBuI-45 SMeI-46 SEtI-47 PhI-51 CNI-52 CF.sub.3I-53 OCH.sub.2 CF.sub.3I-54 SCH.sub.2 CF.sub.3I-55 BrI-56 ClI-57 II-61 H for 2-OMe for HI-62 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-63 No. I-61 No. I-61 OCH.sub.2 CH.dbd.CMe.sub.2I-64 through through MeI-65 Compound Compound EtI-66 No. I-87 No. I-87 t-BuI-67 OMeI-71 OEtI-72 OPrI-73 O-i-PrI-74 OBuI-75 SMeI-76 SEtI-77 PhI-81 CNI-82 CF.sub.3I-83 OCH.sub.2 CF.sub.3I-84 SCH.sub.2 CF.sub.3I-85 BrI-86 ClI-87 II-91 H for 2-CF.sub.3 for HI-92 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-93 No. I-91 No. I-91 OCH.sub.2 CH.dbd.CMe.sub.2I-94 through through MeI-95 Compound Compound EtI-96 No. I-117 No. I-117 t-BuI-97 OMeI-101 OEtI-102 OPrI-103 O-i-PrI-104 OBuI-105 SMeI-106 SEtI-107 PhI-111 CNI-112 CF.sub.3I-113 OCH.sub.2 CF.sub.3I-114 SCH.sub.2 CF.sub.3I-115 BrI-116 ClI-117 II-121 H for 2-Br for HI-122 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-123 No. I-121 No. I-121 OCH.sub.2 CH.dbd.CMe.sub.2I-124 through through MeI-125 Compound Compound EtI-126 No. I-147 No. I-147 t-BuI-127 OMeI-131 OEtI-132 OPrI-133 O-i-PrI-134 OBuI-135 SMeI-136 SEtI-137 PhI-141 CNI-142 CF.sub.3I-143 OCH.sub.2 CF.sub.3I-144 SCH.sub.2 CF.sub.3I-145 BrI-146 ClI-147 II-151 H for 2-C1 for HI-152 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-153 No. I-151 No. I-151 OCH.sub.2 CH--CMe.sub.2I-154 through through MeI-155 Compound Compound EtI-156 No. I-177 No. I-177 t-BuI-157 OMeI-161 OEtI-162 OPrI-163 O-i-PrI-164 OBuI-165 SMeI-166 SEtI-167 PhI-171 CNI-172 CF.sub.3I-173 OCH.sub.2 CF.sub.3I-174 SCH.sub.2 CF.sub.3I-175 BrI-176 ClI-177 II-181 H for 2-F for HI-182 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-183 No. I-181 No. I-181 OCH.sub.2 CH.dbd.CMe.sub.2I-184 through through MeI-185 Compound Compound EtI-186 No. I-207 No. I-207 t-BuI-187 OMeI-191 OEtI-192 OPrI-193 O-i-PrI-194 OBuI-195 SMeI-196 SEtI-197 PhI-201 CNI-202 CF.sub.3I-203 OCH.sub.2 CF.sub.3I-204 SCH.sub.2 CF.sub.3I-205 BrI-206 ClI-207 II-211 H for H for HI-212 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-213 No. I-211 No. I-211 OCH.sub.2 CH.dbd.CMe.sub.2I-214 through through MeI-215 Compound Compound EtI-216 No. I-237 No. I-237 t-BuI-217 OMeI-221 OEtI-222 OPrI-223 O-i-PrI-224 OBuI-225 SMeI-226 SEtI-227 PhI-231 CNI-232 CF.sub.3I-233 OCH.sub.2 CF.sub.3I-234 SCH.sub.2 CF.sub.3I-235 BrI-236 ClI-237 II-241 H for 3-OMe for HI-242 Compound Compound OCH.sub.2 CH--CH.sub.2I-243 No. I-241 No. I-241 OCH.sub.2 CH.dbd.CMe.sub.2I-244 through through MeI-245 Compound Compound EtI-246 No. I-267 No. I-267 t-BuI-247 OMeI-251 OEtI-252 OPrI-253 O-i-PrI-254 OBuI-255 SMeI-256 SEtI-257 PhI-261 CNI-262 CF.sub.3I-263 OCH.sub.2 CF.sub.3I-264 SCH.sub.2 CF.sub.3I-265 BrI-266 ClI-267 II-271 H for 3-SMe for HI-272 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-273 No. I-271 No. I-271 OCH.sub.2 CH.dbd.CMe.sub.2I-274 through through MeI-275 Compound Compound EtI-276 No. I-297 No. I-297 t-BuI-277 OMeI-281 OEtI-282 OPrI-283 O-i-PrI-284 OBuI-285 SMeI-286 SEtI-287 PhI-291 CNI-292 CF.sub.3I-293 OCH.sub.2 CF 3I-294 SCH.sub.2 CF.sub.3I-295 BrI-296 ClI-297 II-301 H for 3-CF.sub.3 for HI-302 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-303 No. I-301 No. I-301 OCH.sub.2 CH.dbd.CMe.sub.2I-304 through through MeI-305 Compound Compound EtI-306 No. I-327 No. I-327 t-BuI-307 OMeI-311 OEtI-312 OPrI-313 O-i-PrI-314 OBuI-315 SMeI-316 SEtI-317 PhI-321 CNI-322 CF.sub.3I-323 OCH.sub.2 CF.sub.3I-324 SCH.sub.2 CF.sub.3I-325 BrI-326 ClI-327 II-331 H for 3-OCF.sub.3 for HI-332 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-333 No. I-331 No. I-331 OCH.sub.2 CH.dbd.CMe.sub.2I-334 through through MeI-335 Compound Compound EtI-336 No. I-357 No. I-357 t-BuI-337 OMeI-341 OEtI-342 OPrI-343 O-i-PrI-344 OBuI-345 SMeI-346 SEtI-347 PhI-351 CNI-352 CF.sub.3I-353 OCH.sub.2 CF.sub.3I-354 SCH.sub.2 CF.sub.3I-355 BrI-356 ClI-357 II-361 H for 3-S.sub.6 F.sub.3 for HI-362 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-363 No. I-361 No. I-361 OCH.sub.2 CH.dbd.CMe.sub.2I-364 through through MeI-365 Compound Compound EtI-366 No. I-387 No. I-387 t-BuI-367 OMeI-371 OEtI-312 OPrI-373 O-i-PrI-374 OBuI-375 SMeI-376 SEtI-377 PhI-381 CNI-382 CF.sub.3I-383 OCH.sub.2 CF.sub.3I-384 SCH.sub.2 CF.sub.3I-385 BrI-386 ClI-387 II-391 H for 3-Br for HI-392 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-393 No. I-391 No. I-391 OCH.sub.2 CH.dbd.CMe.sub.2I-394 through through MeI-395 Compound CompoundI-396 No. I-417 No. I-417 t-BuI-397 OMeI-401 OEtI-402 OPrI-403 O-i-PrI-404 OBuI-405 SMeI-406 SEtI-407 PhI-411 CNI-412 CF.sub.3I-413 OCH.sub.2 CF.sub.3I-414 SCH.sub.2 CF.sub.3I-415 BrI-416 ClI-417 II-421 H for 3-Cl for HI-422 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-423 No. I-421 No. I-421 OCH.sub.2 CH.dbd.CMe.sub.2I-424 through through MeI-425 Compound Compound EtI-426 No. I-447 No. I-447 t-BuI-427 OMeI-431 OEtI-432 OPrI-433 O-i-PrI-434 OBuI-435 SMeI-436 SEtI-437 PhI-441 CNI-442 CF.sub.3I-443 OCH.sub.2 CF.sub.3I-444 SCH.sub.2 CF.sub.3I-445 BrI-446 ClI-447 II-451 H for 3-F for HI-452 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-453 No. I-451 No. I-451 OCH.sub.2 CH.dbd.CMe.sub.2I-454 through through MeI-455 Compound Compound EtI-456 No. I-477 No. I-477 t-BuI-457 OMeI-461 OEtI-462 OPrI-463 O-i-PrI-464 OBuI-465 SMeI-466 SEtI-467 PhI-471 CNI-472 CF.sub.3I-473 OCH.sub.2 CF.sub.3I-474 SCH.sub.2 CF.sub.3I-475 BrI-476 ClI-477 II-481 H for 3-I for HI-482 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-483 No. I-481 No. I-481 OCH.sub.2 CH.dbd.CMe.sub.2I-484 through through MeI-485 Compound Compound EtI-486 No. I-507 No. I-507 t-BuI-487 OMeI-491 OEtI-492 OPrI-493 O-i-PrI-494 OBuI-495 SMeI-496 SEtI-497 PhI-501 CNI-502 CF.sub.3I-503 OCH.sub.2 CF.sub.3I-504 SCH.sub.2 CF.sub.3I-505 BrI-506 ClI-507 II-511 H for 4-Me for HI-512 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-513 No. I-511 No. I-511 OCH.sub.2 CH.dbd.CMe.sub.2I-514 through through MeI-515 Compound Compound EtI-516 No. I-537 No. I-537 t-BuI-517 OMeI-521 OEtI-522 OPrI-523 O-i-PrI-524 OBuI-525 SMeI-526 SEtI-527 PhI-531 CNI-532 CF.sub.3I-533 OCH.sub.2 CF.sub.3I-534 SCH.sub.2 CF.sub.3I-535 BrI-536 ClI-537 II-541 H for 4-OMe for HI-542 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-543 No. I-541 No. I-541 OCH.sub.2 CH.dbd.CMe.sub.2I-544 through through MeI-545 Compound Compound EtI-546 No. I-567 No. I-567 t-BuI-547 OMeI-551 OEtI-552 OPrI-553 O-i-PrI-554 OBuI-555 SMeI-556 SEtI-557 PhI-561 CNI-562 CF.sub.3I-563 OCH.sub.2 CF.sub.3I-564 SCH.sub.2 CF.sub.3I-565 BrI-566 ClI-567 II-571 H for 4-CF.sub.3 for HI-572 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-573 No. I-571 No. I-571 OCH.sub.2 CH.dbd.CMe.sub.2I-574 through through MeI-575 Compound Compound EtI-576 No. I-597 No. I-597 t-BuI-577 OMeI-581 OEtI-582 OPrI-583 O-i-PrI-584 OBuI-585 SMeI-586 SEtI-587 PhI-591 CNI-592 CF.sub.3I-593 OCH.sub.2 CF.sub.3I-594 SCH.sub.2 CF.sub.3I-595 BrI-596 ClI-597 II-601 H for 4-OCF.sub.3 for HI-602 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-603 No. I-601 No. I-601 OCH.sub.2 CH.dbd.CMe.sub.2I-604 through through MeI-605 Compound Compound EtI-606 No. I-627 No. I-627 t-BuI-607 OMeI-611 OEtI-612 OPrI-613 O-i-PrI-614 OBuI-615 SMeI-616 SEtI-617 PhI-621 CNI-622 CF.sub.3I-623 OCH.sub.2 CF.sub.3I-624 SCH.sub.2 CF.sub.3I-625 BrI-626 ClI-627 II-631 H for 4-SCF.sub.3 for HI-632 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-633 No. I-631 No. I-631 OCH.sub.2 CH.dbd.CMe.sub.2I-634 through through MeI-635 Compound Compound EtI-636 No. I-657 No. I-657 t-BuI-637 OMeI-641 OEtI-642 OPrI-643 O-i-PrI-644 OBuI-645 SMeI-646 SEtI-647 PhI-651 ONI-652 CF.sub.3I-653 OCH.sub.2 CF.sub.3I-654 SCH.sub.2 CF.sub.3I-655 BrI-656 ClI-657 II-661 H for 4-SCH.sub.2 CF.sub.3 HI-662 Compound for OCH.sub.2 CH.dbd.CH.sub.2I-663 No. I-661 Compound OCH.sub.2 CH.dbd.CMe.sub.2I-664 through No. I-661 MeI-665 Compound through EtI-666 No. I-687 Compound t-BuI-667 No. I-687 OMeI-671 OEtI-672 OPrI-673 O-i-PrI-674 OBuI-675 SMeI-676 SEtI-677 PhI-681 CNI-682 CF.sub.3I-683 OCH.sub.2 CF.sub.3I-684 SCH.sub.2 CF.sub.3I-685 BrI-686 ClI-687 II-691 H for 4-Br for HI-692 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-693 No. I-691 No. I-691 OCH.sub.2 CH.dbd.CMe.sub.2I-694 through through MeI-695 Compound Compound EtI-696 No. I-717 No. I-717 t-BuI-697 OMeI-701 OEtI-702 OPrI-703 O-i-PrI-704 OBuI-705 SMeI-706 SEtI-707 PhI-711 CNI-712 CF.sub.3I-713 OCH.sub.2 CF.sub.3I-714 SCH.sub.2 CF.sub.3I-715 BrI-716 ClI-717 II-721 H for 4-Cl for HI-722 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-723 No. I-721 No. I-721 OCH.sub.2 CH.dbd.CMe.sub.2I-724 through through MeI-725 Compound Compound EtI-726 No. I-747 No. I-747 t-BuI-727 OMeI-731 OEtI-732 OPrI-733 O-i-PrI-734 OBuI-735 SMeI-736 SEtI-737 PhI-741 CNI-742 CF.sub.3I-743 OCH.sub.2 CF.sub.3I-744 SCH.sub.2 CF.sub.3I-745 BrI-746 ClI-747 II-751 H for 4-F for HI-752 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-753 No. I-751 No. I-751 OCH.sub.2 CH.dbd.CMe.sub.2I-754 through through MeI-755 Compound Compound EtI-756 No. I-777 No. I-777 t-BuI-757 OMeI-761 OEtI-762 OPrI-763 O-i-PrI-764 OBuI-765 SMeI-766 SEtI-767 PhI-771 CNI-772 CF.sub.3I-773 OCH.sub.2 CF.sub.3I-774 SCH.sub.2 CF.sub.3I-775 BrI-776 ClI-777 II-781 H for 4-I for HI-782 Compound Compound OCH.sub.2 CH.dbd.CH.sub.2I-783 No. I-781 No. I-781 OCH.sub.2 CH.dbd.CMe.sub.2I-784 through through MeI-785 Compound Compound EtI-786 No. I-807 No. I-807 t-BuI-787 OMeI-791 OEtI-792 OPrI-793 O-i-PrI-794 OBuI-795 SMeI-796 SEtI-797 PhI-801 CNI-802 CF.sub.3I-803 OCH.sub.2 CF.sub.3I-804 SCH.sub.2 CF.sub.3I-805 BrI-806 ClI-807 II-811 2-Me H OCH.sub.2 CH.dbd.CH.sub.2I-812 2-Me H MeI-813 2-Me H OMeI-814 2-Me H OEtI-815 2-Me H CF.sub.3I-816 2-Me H ClI-817 2-Me 3-Me OCH.sub.2 CH.dbd.CH.sub.2I-821 2-Me 3-Me MeI-822 2-Me 3-Me OMeI-823 2-Me 3-Me OEtI-824 2-Me 3-Me CF.sub.3I-825 2-Me 3-Me ClI-826 2-Me 3-OMe OCH.sub.2 CH.dbd.CH.sub.2I-827 2-Me 3-OMe MeI-831 2-Me 3-OMe OMeI-832 2-Me 3-OMe OEtI-833 2-Me 3-OMe CF.sub.3I-834 2-Me 3-OMe ClI-835 2-Me 3-CF.sub.3 OCH.sub.2 CH.dbd.CH.sub.2I-836 2-Me 3-CF.sub.3 MeI-837 2-Me 3-CF.sub.3 OMeI-841 2-Me 3-CF.sub.3 OEtI-842 2-Me 3-CF.sub.3 CF.sub.3I-843 2-Me 3-CF.sub.3 ClI-844 2-Me 3-Cl OCH.sub.2 CH.dbd.CH.sub.2I-845 2-Me 3-Cl MeI-846 2-Me 3-Cl OMeI-847 2-Me 3-Cl OEtI-851 2-Me 3-Cl CF.sub.3I-852 2-Me 3-Cl ClI-853 2-OMe H OCH.sub.2 CH.dbd.CH.sub.2I-854 2-OMe H MeI-855 2-OMe H OMeI-856 2-OMe H OEtI-857 2-OMe H CF.sub.3I-861 2-OMe H ClI-862 2-OMe 3-Me OCH.sub.2 CH.dbd.CH.sub.2I-863 2-OMe 3-Me MeI-864 2-OMe 3-Me OMeI-865 2-OMe 3-Me OEtI-866 2-OMe 3-Me CF.sub.3I-867 2-OMe 3-Me ClI-871 2-OMe 3-OMe OCH.sub.2 CH.dbd.CH.sub.2I-872 2-OMe 3-OMe MeI-873 2-OMe 3-OMe OMeI-874 2-OMe 3-OMe OEtI-875 2-OMe 3-OMe CF.sub.3I-876 2-OMe 3-OMe ClI-877 2-OMe 3-CF.sub.3 OCH.sub.2 CH.dbd.CH.sub.2I-881 2-OMe 3-CF.sub.3 MeI-882 2-OMe 3-CF.sub.3 OMeI-883 2-OMe 3-CF.sub.3 OEtI-884 2-OMe 3-CF.sub.3 CF.sub.3I-885 2-OMe 3-CF.sub.3 ClI-886 2-OMe 3-Cl OCH.sub.2 CH.dbd.CH.sub.2I-887 2-OMe 3-Cl MeI-891 2-OMe 3-Cl OMeI-892 2-OMe 3-Cl OEtI-893 2-OMe 3-Cl CF.sub.3I-894 2-OMe 3-CL ClI-895 2-Br H OCH.sub.2 CH.dbd.CH.sub.2I-896 2-Br H MeI-897 2-Br H OMeI-901 2-Br H OEtI-902 2-Br H CF.sub.3I-903 2-Br H ClI-904 2-Br 3-Me OCH.sub.2 CH.dbd.CH.sub.2J-905 2-Br 3-Me MeI-906 2-Br 3-Me OMeI-907 2-Br 3-Me OEtI-911 2-Br 3-Me CF.sub.3I-912 2-Br 3-Me ClI-913 2-Br 3-OMe OCH.sub.2 CH.dbd.CH.sub.2I-914 2-Br 3-OMe MeI-915 2-Br 3-OMe OMeI-916 2-Br 3-OMe OEtI-917 2-Br 3-OMe CF.sub.3I-921 2-Br 3-OMe ClI-922 2-Br 3-CF.sub.3 OCH.sub.2 CH.dbd.CH.sub.2I-923 2-Br 3-CF.sub.3 MeI-924 2-Br 3-CF.sub.3 OMeI-925 2-Br 3-CF.sub.3 OEtI-926 2-Br 3-CF.sub.3 CF.sub.3I-927 2-Br 3-CF.sub.3 ClI-931 2-Br 3-Cl OCH.sub.2 CH.dbd.CH.sub.2I-932 2-Br 3-Cl MeI-933 2-Br 3-Cl OMeI-934 2-Br 3-Cl OEtI-935 2-Br 3-Cl CF.sub.3I-936 2-Br 3-Cl ClI-937 2-Cl H OCH.sub.2 CH.dbd.CH.sub.2I-941 2-Cl H MeI-942 2-Cl H OMeI-943 2-Cl H OEtI-944 2-Cl H CF.sub.3I-945 2-Cl H ClI-946 2-Cl 3-Me OCH.sub.2 CH.dbd.CH.sub.2I-947 2-Cl 3-Me MeI-951 2-Cl 3-Me OMeI-952 2-Cl 3-Me OEtI-953 2-Cl 3-Me CF.sub.3I-954 2-Cl 3-Me ClI-955 2-Cl 3-OMe OCH.sub.2 CH.dbd.CH.sub.2I-956 2-Cl 3-OMe MeI-957 2-Cl 3-OMe OMeI-961 2-Cl 3-OMe OEtI-962 2-Cl 3-OMe CF.sub.3I-963 2-Cl 3-OMe ClI-964 2-Cl 3-CF.sub.3 OCH.sub.2 CH.dbd.CH.sub.2I-965 2-Cl 3-CF.sub.3 MeI-966 2-Cl 3-CF.sub.3 OMeI-967 2-Cl 3-CF.sub.3 OEtI-971 2-Cl 3-CF.sub.3 CF.sub.3I-972 2-Cl 3-CF.sub.3 ClI-973 2-Cl 3-Cl OCH.sub.2 CH.dbd.CH.sub.2I-974 2-Cl 3-Cl MeI-975 2-Cl 3-Cl OMeI-976 2-Cl 3-Cl OEtI-977 2-Cl 3-Cl CF.sub.3I-981 2-Cl 3-Cl ClI-982 2-F H OCH.sub.2 CH.dbd.CH.sub.2I-983 2-F H MeI-984 2-F H OMeI-985 2-F H OEtI-986 2-F H CF.sub.3I-987 2-F H ClI-991 2-F 3-Me OCH.sub.2 CH.dbd.CH.sub.2I-992 2-F 3-Me MeI-993 2-F 3-Me OMeI-994 2-F 3-Me OEtI-995 2-F 3-Me CF.sub.3I-996 2-F 3-Me ClI-997 2-F 3-OMe OCH.sub.2 CH.dbd.CH.sub.2I-1001 2-F 3-OMe MeI-1002 2-F 3-OMe OMeI-1003 2-F 3-OMe OEtI-1004 2-F 3-OMe CF.sub.3I-1005 2-F 3-OMe ClI-1006 2-F 3-CF.sub.3 OCH.sub.2 CH.dbd.CH.sub.2I-1007 2-F 3-CF.sub.3 MeI-1011 2-F 3-CF.sub.3 OMeI-1012 2-F 3-CF.sub.3 OEtI-1013 2-F 3-CF.sub.3 CF.sub.3I-1014 2-F 3-CF.sub.3 ClI-1015 2-F 3-Cl OCH.sub.2 CH.dbd.CH.sub.2I-1016 2-F 3-Cl MeI-1017 2-F 3-Cl OMeI-1021 2-F 3-Cl OEtI-1022 2-F 3-Cl CF.sub.3I-1023 2-F 3-Cl ClI-1024 3-I H OCH.sub.2 CH.dbd.CH.sub.2I-1025 3-I H MeI-1026 3-I H OMeI-1027 3-I H OEtI-1031 3-I H CF.sub.3I-1032 3-I H ClI-1033 3-I 3-Me OCH.sub.2 CH.dbd.CH.sub.2I-1034 3-I 3-Me MeI-1035 3-I 3-Me OMeI-1036 3-I 3-Me OEtI-1037 3-I 3-Me CF.sub.3I-1041 3-I 3-Me ClI-1042 3-I 3-OMe OCH.sub.2 CH.dbd.CH.sub.2I-1043 3-T 3-OMe MeI-1044 3-I 3-OMe OMeI-1045 3-I 3-OMe OEtI-1046 3-I 3-OMe CF.sub.3I-1047 3-I 3-OMe ClI-1051 3-I 3-CF.sub.3 OCH.sub.2 CH.dbd.CH.sub.2I-1052 3-I 3-CF.sub.3 MeI-1053 3-I 3-CF.sub.3 OMeI-1054 3-I 3-CF.sub.3 OEtI-1055 3-I 37CF.sub.3 CF.sub.3I-1056 3-I 3-CF.sub.3 ClI-1057 3-I 3-Cl OCH.sub.2 CH.dbd.CH.sub.2I-1061 3-I 3-Cl MeI-1062 3-I 3-Cl OMeI-1063 3-I 3-Cl OEtI-1064 3-I 3-Cl CF.sub.3I-1065 3-I 3-Cl ClI-1066 3-Me H MeI-1067 3-Me H EtI-1071 3-Me H OMeI-1072 3-Me H OEtI-1073 3-Me H SMeI-1074 3-Me H SEtI-1075 3-Me H CNI-1076 3-Me H CF.sub.3I-1077 3-Me H ClI-1081 3-Me 3-Me MeI-1082 3-Me 3-Me EtI-1083 3-Me 3-Me OMeI-1084 3-Me 3-Me OEtI-1085 3-Me 3-Me SMeI-1086 3-Me 3-Me SEtI-1087 3-Me 3-Me CNI-1091 3-Me 3-Me CF.sub.3I-1092 3-Me 3-Me ClI-1093 3-Me 3-OMe MeI-1094 3-Me 3-OMe EtI-1095 3-Me 3-OMe OMeI-1096 3-Me 3-OMe OEtI-1097 3-Me 3-OMe SMeI-1101 3-Me 3-OMe SEtI-1102 3-Me 3-OMe CNI-1103 3-Me 3-OMe CF.sub.3I-1104 3-Me 3-OMe ClI-1105 3-Me 3-CF.sub.3 MeI-1106 3-Me 3-CF.sub.3 EtI-1107 3-Me 3-CF.sub.3 OMeI-1111 3-Me 3-CF.sub.3 OEtI-1112 3-Me 3-CF.sub.3 SMeI-1113 3-Me 3-CF.sub.3 SEtI-1114 3-Me 3-CF.sub.3 CNI-1115 3-Me 3-CF.sub.3 CF.sub.3I-1116 3-Me 3-CF.sub.3 ClI-1117 3-Me 3-Cl MeI-1121 3-Me 3-Cl EtI-1122 3-Me 3-Cl OMeI-1123 3-Me 3-Cl OEtI-1124 3-Me 3-Cl SMeI-1125 3-Me 3-Cl SEtI-1126 3-Me 3-Cl CNI-1127 3-Me 3-Cl CF.sub.3I-1131 3-Me 3-Cl ClI-1132 3-OMe H MeI-1133 3-OMe H EtI-1134 3-OMe H OMeI-1135 3-OMe H OEtI-1136 3-OMe H SMeI-1137 3-OMe H SEtI-1141 3-OMe H CNI-1142 3-OMe H CF.sub.3I-1143 3-OMe H ClI-1144 3-OMe 3-Me MeI-1145 3-OMe 3-Me EtI-1146 3-OMe 3-Me OMeI-1147 3-OMe 3-Me OEtI-1151 3-OMe 3-Me SMeI-1152 3-OMe 3-Me SEtI-1153 3-OMe 3-Me CNI-1154 3-OMe 3-Me CF.sub.3I-1155 3-OMe 3-Me ClI-1156 3-OMe 3-OMe MeI-1157 3-OMe 3-OMe EtI-1161 3-OMe 3-OMe OMeI-1162 3-OMe 3-OMe OEtI-1163 3-OMe 3-OMe SMeI-1164 3-OMe 3-OMe SEtI-1165 3-OMe 3-OMe CNI-1166 3-OMe 3-OMe CF.sub.3I-1167 3-OMe 3-OMe ClI-1171 3-OMe 3-CF.sub.3 MeI-1172 3-OMe 3-CF.sub.3 EtI-1173 3-OMe 3-CF.sub.3 OMeI-1174 3-OMe 3-CF.sub.3 OEtI-1175 3-OMe 3-CF.sub.3 SMeI-1176 3-OMe 3-CF.sub.3 SEtI-1177 3-OMe 3-CF.sub.3 CNI-1181 3-OMe 3-CF.sub.3 CF.sub.3I-1182 3-OMe 3-CF.sub.3 ClI-1183 3-OMe 3-Cl MeI-1184 3-OMe 3-Cl EtI-1185 3-OMe 3-Cl OMeI-1186 3-OMe 3-CL OEtI-1187 3-OMe 3-Cl SMeI-1191 3-OMe 3-Cl SEtI-1192 3-OMe 3-Cl CNI-1193 3-OMe 3-Cl CF.sub.3I-1194 3-OMe 3-Cl ClI-1195 3-CF.sub.3 H MeI-1196 3-CF.sub.3 H EtI-1197 3-CF.sub.3 H OMeI-1201 3-CF.sub.3 H OEtI-1202 3-CF.sub.3 H SMeI-1203 3-CF.sub.3 H SEtI-1204 3-CF.sub.3 H CNI-1205 3-CF.sub.3 H CF.sub.3I-1206 3-CF.sub.3 H ClI-1207 3-CF.sub.3 3-Me MeI-1211 3-CF.sub.3 3-Me EtI-1212 3-CF.sub.3 3-Me OMeI-1213 3-CF.sub.3 3-Me OEtI-1214 3-CF.sub.3 3-Me SMeI-1215 3-CF.sub.3 3-Me SEtI-1216 3-CF.sub.3 3-Me CNI-1217 3-CF.sub.3 3-Me CF.sub.3I-1221 3-CF.sub.3 3-Me ClI-1222 3-CF.sub.3 3-OMe MeI-1223 3-CF.sub.3 3-OMe EtI-1224 3-CF.sub.3 3-OMe OMeI-1225 3-CF.sub.3 3-OMe OEtI-1226 3-CF.sub.3 3-OMe SMeI-1227 3-CF.sub.3 3-OMe SEtI-1231 3-CF.sub.3 3-OMe CNI-1232 3-CF.sub.3 3-OMe CF.sub.3I-1233 3-CF.sub.3 3-OMe ClI-1234 3-CF.sub.3 3-CF.sub.3 MeI-1235 3-CF.sub.3 3-CF.sub.3 EtI-1236 3-CF.sub.3 3-CF.sub.3 OMeI-1237 3-CF.sub.3 3-CF.sub.3 OEtI-1241 3-CF.sub.3 3-CF.sub.3 SMeI-1242 3-CF.sub.3 3-CF.sub.3 SEtI-1243 3-CF.sub.3 3-CF.sub.3 CNI-1244 3-CF.sub.3 3-CF.sub.3 CF.sub.3I-1245 3-CF.sub.3 3-CF.sub.3 ClI-1246 3-CF.sub.3 3-Cl MeI-1247 3-CF.sub.3 3-Cl EtI-1251 3-CF.sub.3 3-Cl OMeI-1252 3-CF.sub.3 3-Cl OEtI-1253 3-CF.sub.3 3-Cl SMeI-1254 3-CF.sub.3 3-Cl SEtI-1255 3-CF.sub.3 3-Cl CNI-1256 3-CF.sub.3 3-Cl CF.sub.3I-1257 3-CF.sub.3 3-Cl ClI-1261 3-Br H MeI-1262 3-Br H EtI-1263 3-Br H OMeI-1264 3-Br H OEtI-1265 3-Br H SMeI-1266 3-Br H SEtI-1267 3-Br H CNI-1271 3-Br H CF.sub.3I-1272 3-Br H ClI-1273 3-Br 3-Me MeI-1274 3-Br 3-Me EtI-1275 3-Br 3-Me OMeI-1276 3-Br 3-Me OEtI-1277 3-Br 3-Me SMeI-1281 3-Br 3-Me SEtI-1282 3-Br 3-Me CNI-1283 3-Br 3-Me CF.sub.3I-1284 3-Br 3-Me ClI-1285 3-Br 3-OMe MeI-1286 3-Br 3-OMe EtI-1287 3-Br 3-OMe OMeI-1291 3-Br 3-OMe OEtI-1292 3-Br 3-OMe SMeI-1293 3-Br 3-OMe SEtI-1294 3-Br 3-OMe CNI-1295 3-Br 3-OMe CF.sub.3I-1296 3-Br 3-OMe ClI-1297 3-Br 3-CF.sub.3 MeI-1301 3-Br 3-CF.sub.3 EtI-1302 3-Br 3-CF.sub.3 OMeI-1303 3-Br 3-CF.sub.3 OEtI-1304 3-Br 3-CF.sub.3 SMeI-1305 3-Br 3-CF.sub.3 SEtI-1306 3-Br 3-CF.sub.3 CNI-1307 3-Br 3-CF.sub.3 CF.sub.3I-1311 3-Br 3-CF.sub.3 ClI-1312 3-Br 3-Cl MeI-1313 3-Br 3-Cl EtI-1314 3-Br 3-Cl OMeI-1315 3-Br 3-Cl OEtI-1316 3-Br 3-Cl SMeI-1317 3-Br 3-Cl SEtI-1321 3-Br 3-Cl CNI-1322 3-Br 3-Cl CF.sub.3I-1323 3-Br 3-Cl ClI-1324 3-Cl H MeI-1325 3-Cl H EtI-1326 3-Cl H OMeI-1327 3-Cl H OEtI-1331 3-Cl H SMeI-1332 3-Cl H SEtI-1333 3-Cl H CNI-1334 3-Cl H CF.sub.3I-1335 3-Cl H ClI-1336 3-Cl 3-Me MeI-1337 3-Cl 3-Me EtI-1341 3-Cl 3-Me OMeI-1342 3-Cl 3-Me OEtI-1343 3-Cl 3-Me SMeI-1344 3-Cl 3-Me SEtI-1345 3-Cl 3-Me CNI-1346 3-Cl 3-Me CF.sub.3I-1347 3-Cl 3-Me ClI-1351 3-Cl 3-OMe MeI-1352 3-Cl 3-OMe EtI-1353 3-Cl 3-OMe OMeI-1354 3-Cl 3-OMe OEtI-1355 3-Cl 3-OMe SMeI-1356 3-Cl 3-OMe SEtI-1357 3-Cl 3-OMe CNI-1361 3-Cl 3-OMe CF.sub.3I-1362 3-Cl 3-OMe ClI-1363 3-Cl 3-CF.sub.3 MeI-1364 3-Cl 3-CF.sub.3 EtI-1365 3-Cl 3-CF.sub.3 OMeI-1366 3-Cl 3-CF.sub.3 OEtI-1367 3-Cl 3-CF.sub.3 SMeI-1371 3-Cl 3-CF.sub.3 SEtI-1372 3-Cl 3-CF.sub.3 CNI-1373 3-Cl 3-CF.sub.3 CF.sub.3I-1374 3-Cl 3-CF.sub.3 ClI-1375 3-Cl 3-Cl MeI-1376 3-Cl 3-Cl EtI-1377 3-Cl 3-Cl OMeI-1381 3-Cl 3-Cl OEtI-1382 3-Cl 3-Cl SMeI-1383 3-Cl 3-Cl SEtI-1384 3-Cl 3-Cl CNI-1385 3-Cl 3-Cl CF.sub.3I-1386 3-Cl 3-Cl ClI-1387 3-F H MeI-1391 3-F H EtI-1392 3-F H OMeI-1393 3-F H OEtI-1394 3-F H SMeI-1395 3-F H SEtI-1396 3-F H CNI-1397 3-F H CF.sub.3I-1401 3-F H ClI-1402 3-F 3-Me MeI-1403 3-F 3-Me EtI-1404 3-F 3-Me OMeI-1405 3-F 3-Me OEtI-1406 3-F 3-Me SMeI-1407 3-F 3-Me SEtI-1411 3-F 3-Me CNI-1412 3-F 3-Me CF.sub.3I-1413 3-F 3-Me ClI-1414 3-F 3-OMe MeI-1415 3-F 3-OMe EtI-1416 3-F 3-OMe OMeI-1417 3-F 3-OMe OEtI-1421 3-F 3-OMe SMeI-1422 3-F 3-OMe SEtI-1423 3-F 3-OMe CNI-1424 3-F 3-OMe CF.sub.3I-1425 3-F 3-OMe ClI-1426 3-F 3-CF.sub.3 MeI-1427 3-F 3-CF.sub.3 EtI-1431 3-F 3-CF.sub.3 OMeI-1432 3-F 3-CF.sub.3 OEtI-1433 3-F 3-CF.sub.3 SMeI-1434 3-F 3-CF.sub.3 SEtI-1435 3-F 3-CF.sub.3 CNI-1436 3-F 3-CF.sub.3 CF.sub.3I-1437 3-F 3-CF.sub.3 ClI-1441 3-F 3-Cl MeI-1442 3-F 3-Cl EtI-1443 3-F 3-Cl OMeI-1444 3-F 3-Cl OEtI-1445 3-F 3-Cl SMeI-1446 3-F 3-Cl SEtI-1447 3-F 3-Cl CNI-1451 3-F 3-Cl CF.sub.3I-1452 3-F 3-Cl ClI-1453 4-Me H MeI-1454 4-Me H EtI-1455 4-Me H OMeI-1456 4-Me H OEtI-1457 4-Me H SMeI-1461 4-Me H SEtI-1462 4-Me H CNI-1463 4-Me H CF.sub.3I-1464 4-Me H ClI-1465 4-Me 3-Me MeI-1466 4-Me 3-Me EtI-1467 4-Me 3-Me OMeI-1471 4-Me 3-Me OEtI-1472 4-Me 3-Me SMeI-1473 4-Me 3-Me SEtI-1474 4-Me 3-Me CNI-1475 4-Me 3-Me CF.sub.3I-1476 4-Me 3-Me ClI-1477 4-Me 3-OMe MeI-1481 4-Me 3-OMe EtI-1482 4-Me 3-OMe OMeI-1483 4-Me 3-OMe OEtI-1484 4-Me 3-OMe SMeI-1485 4-Me 3-OMe SEtI-1486 4-Me 3-OMe CNI-1487 4-Me 3-OMe CF.sub.3I-1491 4-Me 3-OMe ClI-1492 4-Me 3-CF.sub.3 MeI-1493 4-Me 3-CF.sub.3 EtI-1494 4-Me 3-CF.sub.3 OMeI-1495 4-Me 3-CF.sub.3 OEtI-1496 4-Me 3-CF.sub.3 SMeI-1497 4-Me 3-CF.sub.3 SEtI-1501 4-Me 3-CF.sub.3 CNI-1502 4-Me 3-CF.sub.3 CF.sub.3I-1503 4-Me 3-CF.sub.3 ClI-1504 4-Me 3-Cl MeI-1505 4-Me 3-Cl EtI-1506 4-Me 3-Cl OMeI-1507 4-Me 3-Cl OEtI-1511 4-Me 3-Cl SMeI-1512 4-Me 3-Cl SEtI-1513 4-Me 3-Cl CNI-1514 4-Me 3-Cl CF.sub.3I-1515 4-Me 3-Cl ClI-1516 4-OMe H MeI-1517 4-OMe H EtI-1521 4-OMe H OMeI-1522 4-OMe H OEtI-1523 4-OMe H SMeI-1524 4-OMe H SEtI-1525 4-OMe H CNI-1526 4-OMe H CF.sub.3I-1527 4-OMe H ClI-1531 4-OMe 3-Me MeI-1532 4-OMe 3-Me EtI-1533 4-OMe 3-Me OMeI-1534 4-OMe 3-Me OEtI-1535 4-OMe 3-Me SMeI-1536 4-OMe 3-Me SEtI-1537 4-OMe 3-Me CNI-1541 4-OMe 3-Me CF.sub.3I-1542 4-OMe 3-Me ClI-1543 4-OMe 3-OMe MeI-1544 4-OMe 3-OMe EtI-1545 4-OMe 3-OMe OMeI-1546 4-OMe 3-OMe OEtI-1547 4-OMe 3-OMe SMeI-1551 4-OMe 3-OMe SEtI-1552 4-OMe 3-OMe CNI-1553 4-OMe 3-OMe CF.sub.3I-1554 4-OMe 3-OMe ClI-1555 4-OMe 3-CF.sub.3 MeI-1556 4-OMe 3- CF.sub.3 EtI-1557 4-OMe 3-CF.sub.3 OMeI-1561 4-OMe 3-CF.sub.3 OEtI-1562 4-OMe 3-CF.sub.3 SMeI-1563 4-OMe 3-CF.sub.3 SEtI-1564 4-OMe 3-CF.sub.3 CNI-1565 4-OMe 3-CF.sub.3 CF.sub.3I-1566 4-OMe 3-CF.sub.3 ClI-1567 4-OMe 3-Cl MeI-1571 4-OMe 3-Cl EtI-1572 4-OMe 3-Cl OMeI-1573 4-OMe 3-Cl OEtI-1574 4-OMe 3-Cl SMeI-1575 4-OMe 3-Cl SEtI-1576 4-OMe 3-Cl CNI-1577 4-OMe 3-Cl CF.sub.3I-1581 4-OMe 3-Cl ClI-1582 4-CF.sub.3 H MeI-1583 4-CF.sub.3 H EtI-1584 4-CF.sub.3 H OMeI-1585 4-CF.sub.3 H OEtI-1586 4-CF.sub.3 H SMeI-1587 4-CF.sub.3 H SEtI-1591 4-CF.sub.3 H CNI-1592 4-CF.sub.3 H CF.sub.3I-1593 4-CF.sub.3 H ClI-1594 4-CF.sub.3 3-Me MeI-1595 4-CF.sub.3 3-Me EtI-1596 4-CF.sub.3 3-Me OMeI-1597 4-CF.sub.3 3-Me OEtI-1601 4-CF.sub.3 3-Me SMeI-1602 4-CF.sub.3 3-Me SEtI-1603 4-CF.sub.3 3-Me CNI-1604 4-CF.sub.3 3-Me CF.sub.3I-1605 4-CF.sub.3 3-Me ClI-1606 4-CF.sub.3 3-OMe MeI-1607 4-CF.sub.3 3-OMe EtI-1611 4-CF.sub.3 3-OMe OMeI-1612 4-CF.sub.3 3-OMe OEtI-1613 4-CF.sub.3 3-OMe SMeI-1614 4-CF.sub.3 3-OMe SEtI-1615 4-CF.sub.3 3-OMe CNI-1616 4-CF.sub.3 3-OMe CF.sub.3I-1617 4-CF.sub.3 3-OMe ClI-1621 4-CF.sub.3 3-CF.sub.3 MeI-1622 4-CF.sub.3 3-CF.sub.3 EtI-1623 4-CF.sub.3 3-CF.sub.3 OMeI-1624 4-CF.sub.3 3-CF.sub.3 OEtI-1625 4-CF.sub.3 3-CF.sub.3 SMeI-1626 4-CF.sub.3 3-CF.sub.3 SEtI-1627 4-CF.sub.3 3-CF.sub.3 CNI-1631 4-CF.sub.3 3-CF.sub.3 CF.sub.3I-1632 4-CF.sub.3 3-CF.sub.3 ClI-1633 4-CF.sub.3 3-Cl MeI-1634 4-CF.sub.3 3-Cl EtI-1635 4-CF.sub.3 3-Cl OMeI-1636 4-CF.sub.3 3-Cl OEtI-1637 4-CF.sub.3 3-Cl SMeI-1641 4-CF.sub.3 3-Cl SEtI-1642 4-CF.sub.3 3-Cl CNI-1643 4-CF.sub.3 3-Cl CF.sub.3I-1644 4-CF.sub.3 3-Cl ClI-1645 4-Br H MeI-1646 4-Br H EtI-1647 4-Br H OMeI-1651 4-Br H OEtI-1652 4-Br H SMeI-1653 4-Br H SEtI-1654 4-Br H CNI-1655 4-Br H CF.sub.3I-1656 4-Br H ClI-1657 4-Br 3-Me MeI-1661 4-Br 3-Me EtI-1662 4-Br 3-Me OMeI-1663 4-Br 3-Me OEtI-1664 4-Br 3-Me SMeI-1665 4-Br 3-Me SEtI-1666 4-Br 3-Me CNI-1667 4-Br 3-Me CF.sub.3I-1671 4-Br 3-Me ClI-1672 4-Br 3-OMe MeI-1673 4-Br 3-OMe EtI-1674 4-Br 3-OMe OMeI-1675 4-Br 3-OMe OEtI-1676 4-Br 3-OMe SMeI-1677 4-Br 3-OMe SEtI-1681 4-Br 3-OMe CNI-1682 4-Br 3-OMe CF.sub.3I-1683 4-Br 3-OMe ClI-1684 4-Br 3-CF.sub.3 MeI-1685 4-Br 3-CF.sub.3 EtI-1686 4-Br 3-CF.sub.3 OMeI-1687 4-Br 3-CF.sub.3 OEtI-1692 4-Br 3-CF.sub.3 SMeI-1692 4-Br 3-CF.sub.3 SEtI-1693 4-Br 3-CF.sub.3 CNI-1694 4-Br 3-CF.sub.3 CF.sub.3I-1695 4-Br 3-CF.sub.3 ClI-1696 4-Br 3-Cl MeI-1697 4-Br 3-Cl EtI-1701 4-Br 3-Cl OMeI-1702 4-Br 3-Cl OEtI-1703 4-Br 3-Cl SMeI-1704 4-Br 3-Cl SEtI-1705 4-Br 3-Cl CNI-1706 4-Br 3-Cl CF.sub.3I-1707 4-Br 3-Cl ClI-1711 4-Cl H MeI-1712 4-Cl H EtI-1713 4-Cl H OMeI-1714 4-Cl H OEtI-1715 4-Cl H SMeI-1716 4-Cl H SEtI-1717 4-Cl H CNI-1721 4-Cl H CF.sub.3I-1722 4-Cl H ClI-1723 4-Cl 3-Me MeI-1724 4-Cl 3-Me EtI-1725 4-Cl 3-Me OMeI-1726 4-Cl 3-Me OEtI-1727 4-Cl 3-Me SMeI-1731 4-Cl 3-Me SEtI-1732 4-Cl 3-Me CNI-1733 4-Cl 3-Me CF.sub.3I-1734 4-Cl 3-Me ClI-1735 4-Cl 3-OMe MeI-1736 4-Cl 3-OMe EtI-1737 4-Cl 3-OMe OMeI-1741 4-Cl 3-OMe OEtI-1742 4-Cl 3-OMe SMeI-1743 4-Cl 3-OMe SEtI-1744 4-Cl 3-OMe CNI-1745 4-Cl 3-OMe CF.sub.3I-1746 4-Cl 3-OMe ClI-1747 4-Cl 3-CF.sub.3 MeI-1751 4-Cl 3-CF.sub.3 EtI-1752 4-Cl 3-CF.sub.3 OMeI-1753 4-Cl 3-CF.sub.3 OEtI-1754 4-Cl 3-CF.sub.3 SMeI-1755 4-Cl 3-CF.sub.3 SEtI-1756 4-Cl 3-CF.sub.3 CNI-1757 4-Cl 3-CF.sub.3 CF.sub.3I-1761 4-Cl 3-CF.sub.3 ClI-1762 4-Cl 3-Cl MeI-1763 4-Cl 3-Cl EtI-1764 4-Cl 3-Cl OMeI-1765 4-Cl 3-Cl OEtI-1766 4-Cl 3-Cl SMeI-1767 4-Cl 3-Cl SEtI-1771 4-Cl 3-Cl CNI-1772 4-Cl 3-Cl CF.sub.3I-1773 4-Cl 3-Cl ClI-1774 4-F H MeI-1775 4-F H EtI-1776 4-F H OMeI-1777 4-F H OEtI-1781 4-F H SMeI-1782 4-F H SEtI-1783 4-F H CNI-1784 4-F H CF.sub.3I-1785 4-F H ClI-1786 4-F 3-Me MeI-1787 4-F 3-Me EtI-1791 4-F 3-Me OMeI-1792 4-F 3-Me OEtI-1793 4-F 3-Me SMeI-1794 4-F 3-Me SEtI-1795 4-F 3-Me CNI-1796 4-F 3-Me CF.sub.3I-1797 4-F 3-Me ClI-1801 4-F 3-OMe MeI-1802 4-F 3-OMe EtI-1803 4-F 3-OMe OMeI-1804 4-F 3-OMe OEtI-1805 4-F 3-OMe SMeI-1806 4-F 3-OMe SEtI-1807 4-F 3-OMe CNI-1811 4-F 3-OMe CF.sub.3I-1812 4-F 3-OMe ClI-1813 4-F 3-CF.sub.3 MeI-1814 4-F 3-CF.sub.3 EtI-1815 4-F 3-CF.sub.3 OMeI-1816 4-F 3-CF.sub.3 OEtI-1817 4-F 3-CF.sub.3 SMeI-1821 4-F 3-CF.sub.3 SEtI-1822 4-F 3-CF.sub.3 CNI-1823 4-F 3-CF.sub.3 CF.sub.3I-1824 4-F 3-CF.sub.3 ClI-1825 4-F 3-Cl MeI-1826 4-F 3-Cl EtI-1827 4-F 3-Cl OMeI-1831 4-F 3-Cl OEtI-1832 4-F 3-Cl SMeI-1833 4-F 3-Cl SEtI-1834 4-F 3-Cl CNI-1835 4-F 3-Cl CF.sub.3I-1836 4-F 3-Cl ClI-1837 2,4-(OMe).sub.2 H MeI-1841 2,4-(OMe).sub.2 H OMeI-1842 2,4-(OMe).sub.2 H ClI-1843 2,4-(OMe).sub.2 3-Me MeI-1844 2,4-(OMe).sub.2 3-Me OMeI-1845 2,4-(OMe).sub.2 3-Me ClI-1846 2,4-(OMe).sub.2 3-OMe MeI-1847 2,4-(OMe).sub.2 3-OMe OMeI-1851 2,4-(OMe).sub.2 3-OMe ClI-1852 2,4-(OMe).sub.2 3-CF.sub.3 MeI-1853 2,4-(OMe).sub.2 3-CF.sub.3 OMeI-1854 2,4-(OMe).sub.2 3-CF.sub.3 ClI-1855 2,4-(OMe).sub.2 3-Cl MeI-1856 2,4-(OMe).sub.2 3-Cl OMeI-1857 2,4-(OMe).sub.2 3-Cl ClI-1861 2,4-Cl.sub.2 H MeI-1862 2,4-Cl.sub.2 H OMeI-1863 2,4-Cl.sub.2 H ClI-1864 2,4-Cl.sub.2 3-Me MeI-1865 2,4-Cl.sub.2 3-Me OMeI-1866 2,4-Cl.sub.2 3-Me ClI-1867 2,4-Cl.sub.2 3-OMe MeI-1871 2,4-Cl.sub.2 3-OMe OMeI-1872 2,4-Cl.sub.2 3-OMe ClI-1873 2,4-Cl.sub.2 3-CF.sub.3 MeI-1874 2,4-Cl.sub.2 3-CF.sub.3 OMeI-1875 2,4-Cl.sub.2 3-CF.sub.3 ClI-1876 2,4-Cl.sub.2 3-Cl MeI-1877 2,4-Cl.sub.2 3-Cl OMeI-1881 2,4-Cl.sub.2 3-Cl ClI-1882 2,4-F.sub.2 H MeI-1883 2,4-F.sub.2 H OMeI-1884 2,4-F.sub.2 H ClI-1885 2,4-F.sub.2 3-Me MeI-1886 2,4-F.sub.2 3-Me OMeI-1887 2,4-F.sub.2 3-Me ClI-1891 2,4-F.sub.2 3-OMe MeI-1892 2,4-F.sub.2 3-OMe OMeI-1893 2,4-F.sub.2 3-OMe ClI-1894 2,4-F.sub.2 3-CF.sub.3 MeI-1895 2,4-F.sub.2 3-CF.sub.3 OMeI-1896 2,4-F.sub.2 3-CF.sub.3 ClI-1897 2,4-F.sub.2 3-Cl MeI-1901 2,4-F.sub.2 3-Cl OMeI-1902 3,4-F.sub.2 3-Cl ClI-1903 3,4-Me.sub.2 H MeI-1904 3,4-Me.sub.2 H OMeI-1905 3,4-Me.sub.2 H ClI-1906 3,4-Me.sub.2 3-Me MeI-1907 3,4-Me.sub.2 3-Me OMeI-1911 3,4-Me.sub.2 3-Me ClI-1912 3,4-Me.sub.2 3-OMe MeI-1913 3,4-Me.sub.2 3-OMe OMeI-1914 3,4-Me.sub.2 3-OMe ClI-1915 3,4-Me.sub.2 3-CF.sub.3 MeI-1916 3,4-Me.sub.2 3-CF.sub.3 OMeI-1917 3,4-Me.sub.2 3-CF.sub.3 ClI-1921 3,4-Me.sub.2 3-Cl MeI-1922 3,4-Me.sub.2 3-Cl OMeI-1923 3,4-Me.sub.2 3-Cl ClI-1924 3,4-Cl.sub.2 H MeI-1925 3,4-Cl.sub.2 H OMeI-1926 3,4-Cl.sub.2 H ClI-1927 3,4-Cl.sub.2 3-Me MeI-1931 3,4-Cl.sub.2 3-Me OMeI-1932 3,4-Cl.sub.2 3-Me ClI-1933 3,4-Cl.sub.2 3-OMe MeI-1934 3,4-Cl.sub.2 3-OMe OMeI-1935 3,4-Cl.sub.2 3-OMe ClI-1936 3,4-Cl.sub.2 3-CF.sub.3 MeI-1937 3,4-Cl.sub.2 3-CF.sub.3 OMeI-1941 3,4-Cl.sub.2 3-CF.sub.3 ClI-1942 3,4-Cl.sub.2 3-Cl MeI-1943 3,4-Cl.sub.2 3-Cl OMeI-1944 3,4-Cl.sub.2 3-Cl ClI-1945 3,4-F.sub.2 H MeI-1946 3,4-F.sub.2 H OMeI-1947 3,4-F.sub.2 H ClI-1951 3,4-F.sub.2 3-Me MeI-1952 3,4-F.sub.2 3-Me OMeI-1953 3,4-F.sub.2 3-Me ClI-1954 3,4-F.sub.2 3-OMe MeI-1955 3,4-F.sub.2 3-OMe OMeI-1956 3,4-F.sub.2 3-OMe ClI-1957 3,4-F.sub.2 3-CF.sub.3 MeI-1961 3,4-F.sub.2 3-CF.sub.3 OMeI-1962 3,4-F.sub.2 3-CF.sub.3 ClI-1963 3,4-F.sub.2 3-Cl MeI-1964 3,4-F.sub.2 3-Cl OMeI-1965 3,4-F.sub.2 3-Cl Cl______________________________________
The 2-benzyloxy-4-phenoxypyrimidine derivative represented by the formula (I) (Compound (I) as shown in Table 1 (1/34 to 34/34) can be synthesized in accordance with the following Reaction schemes I or II. ##STR10## wherein R.sup.1, R.sup.2, X, Y n and m are as defined above. ##STR11## wherein R.sup.1 a, R.sup.3, X, Ya, n and m are as defined above.
Either reaction shown by the above schemes is nucleophilic displacement on the pyrimidine ring, thus may be conducted in accordance with the following reaction sequence, for example.
Compounds (I) may be synthesized in a two-phase system containing a phase transfer catalyst such as amides (e.g. dimethylformamide, dimethylacetamide, and N-methyl-2-pyrrolidinone); ethers (e.g. diethylether, dimethoxyethane, diisopropylether, tetrahydrofuran, diglyme, and dioxane); and quaternary ammonium salts (e.g. benzalkonium chloride and tetrabutyl ammonium chloride), in the presence of a basic compound. The basic compound may be present during the nucleophilic displacement on the pyrimidine ring. The basic compound may be used to form a salt by substituting as proton, hydrogen bonded to oxygen of the phenol compound of the formula (III) or of the benzyl alcohol compound of the formula (IV). The reaction may be conducted preferably at a temperature range of -20.degree. C. to 150.degree. C., for a period of about 0.5 hour to one day (about 24 hours).
An iodide such as sodium iodide and potassium iodide or a crown ether such as 18-crown-6 and dibenzo-18-crown-6 may be added to the reaction system as a reaction accelerator.
Examples of the 2-benzyloxy-4(and/or 6)-halogenopyrimidine derivative of the formula (II) (Compound (II)) which can be used as a starting material in the Reaction scheme I are shown in Table 2.
TABLE 2______________________________________No. X.sub.n R.sup.1 R.sup.2______________________________________II-1 H H ClII-2 H OCH.sub.2 CH.dbd.CH.sub.2 ClII-3 H OCH.sub.2 CH.dbd.CMe.sub.2 ClII-4 H Me ClII-5 H Et ClII-6 H t-Bu ClII-7 H OMe ClII-11 H OEt ClII-12 H OPr ClII-13 H O-i-Pr ClII-14 H OBu ClII-15 H SMe ClII-16 H SEt ClII-17 H Ph ClII-21 H CN ClII-22 H CF.sub.3 ClII-23 H OCH.sub.2 CF.sub.3 ClII-24 H SCH.sub.2 CF.sub.3 ClII-25 H Br BrII-26 H Cl ClII-27 H I III-31 2-Me OCH.sub.2 CH.dbd.CH.sub.2 ClII-32 2-Me Me ClII-33 2-Me OMe ClII-34 2-Me OEt ClII-35 2-Me CF.sub.3 ClII-36 2-Me Cl ClII-37 2-OMe OCH.sub.2 CH.dbd.CH.sub.2 ClII-41 2-OMe Me ClII-42 2-OMe OMe ClII-43 2-OMe OEt ClII-44 2-OMe CF.sub.3 ClII-45 2-OMe Cl ClII-46 2-Br OCH.sub.2 CH.dbd.CH.sub.2 ClII-47 2-Br Me ClII-51 2-Br OMe ClII-52 2-Br OEt ClII-53 2-Br CF.sub.3 ClII-54 2-Br Cl ClII-55 2-Cl OCH.sub.2 CH.dbd.CH.sub.2 ClII-56 2-Cl Me ClII-57 2-Cl OMe ClII-61 2-Cl OEt ClII-62 2-Cl CF.sub.3 ClII-63 2-Cl Cl ClII-64 2-F OCH.sub.2 CH.dbd.CH.sub.2 ClII-65 2-F Me ClII-66 2-F OMe ClII-67 2-F OEt ClII-71 2-F CF.sub.3 ClII-72 2-F Cl ClII-73 3-I OCH.sub.2 CH.dbd.CH.sub.2 ClII-74 3-I Me ClII-75 3-I OMe ClII-76 3-I OEt ClII-77 3-I CF.sub.3 ClII-81 3-I Cl ClII-82 3-Me Me ClII-83 3-Me Et ClII-84 3-Me OMe ClII-85 3-Me OEt ClII-86 3-Me SMe ClII-87 3-Me SEt ClII-91 3-Me CN ClII-92 3-Me CF.sub.3 ClII-93 3-Me Cl ClII-94 3-OMe Me ClII-95 3-OMe Et ClII-96 3-OMe OMe ClII-97 3-OMe OEt ClII-101 3-OMe SMe ClII-102 3-OMe SEt ClII-103 3-OMe CN ClII-104 3-OMe CF.sub.3 ClII-105 3-OMe Cl ClII-106 3-CF.sub.3 Me ClII-107 3-CF.sub.3 Et ClII-111 3-CF.sub.3 OMe ClII-112 3-CF.sub.3 OEt ClII-113 3-CF.sub.3 SMe ClII-114 3-CF.sub.3 SEt ClII-115 3-CF.sub.3 CN ClII-116 3-CF.sub.3 CF.sub.3 ClII-117 3-CF.sub.3 Cl ClII-121 3-Br Me ClII-122 3-Br Et ClII-123 3-Br OMe ClII-124 3-Br OEt ClII-125 3-Br SMe ClII-126 3-Br SEt ClII-127 3-Br CN ClII-131 3-Br CF.sub.3 ClII-132 3-Br Cl ClII-133 3-Cl Me ClII-134 3-Cl Et ClII-135 3-Cl OMe ClII-136 3-Cl OEt ClII-137 3-Cl SMe ClII-141 3-Cl SEt ClII-142 3-Cl CN ClII-143 3-Cl CF.sub.3 ClII-144 3-Cl Cl ClII-145 3-F Me ClII-146 3-F Et ClII-147 3-F OMe ClII-151 3-F OEt ClII-152 3-F SMe ClII-153 3-F SEt ClII-154 3-F CN ClII-155 3-F CF.sub.3 ClII-156 3-F Cl ClII-157 4-Me Me ClII-161 4-Me Et ClII-162 4-Me OMe ClII-163 4-Me OEt ClII-164 4-Me SMe ClII-165 4-Me SEt ClII-166 4-Me CN ClII-167 4-Me CF.sub.3 ClII-171 4-Me Cl ClII-172 4-OMe Me ClII-173 4-OMe Et ClII-174 4-OMe OMe ClII-175 4-OMe OEt ClII-176 4-OMe SMe ClII-177 4-OMe SEt ClII-181 4-OMe CN ClII-182 4-OMe CF.sub.3 ClII-183 4-OMe Cl ClII-184 4-CF.sub.3 Me ClII-185 4-CF.sub.3 Et ClII-186 4-CF.sub.3 OMe ClII-187 4-CF.sub.3 OEt ClII-191 4-CF.sub.3 SMe ClII-192 4-CF.sub.3 SEt ClII-193 4-CF.sub.3 CN ClII-194 4-CF.sub.3 CF.sub.3 ClII-195 4-CF.sub.3 Cl ClII-196 4-Br Me ClII-197 4-Br Et ClII-201 4-Br OMe ClII-202 4-Br OEt ClII-203 4-Br SMe ClII-204 4-Br SEt ClII-205 4-Br CN ClII-206 4-Br CF.sub.3 ClII-207 4-Br Cl ClII-211 4-Cl Me ClII-212 4-Cl Et ClII-213 4-Cl OMe ClII-214 4-Cl OEt ClII-215 4-Cl SMe ClII-216 4-Cl SEt ClII-217 4-Cl CN ClII-221 4-Cl CF.sub.3 ClII-222 4-Cl Cl ClII-223 4-F Me ClII-224 4-F Et ClII-225 4-F OMe ClII-226 4-F OEt ClII-227 4-F SMe ClII-231 4-F SEt ClII-232 4-F CN ClII-233 4-F CF.sub.3 ClII-234 4-F Cl ClII-235 2,4-(OMe).sub.2 Me ClII-236 2,4-(OMe).sub.2 OMe ClII-237 2,4-(OMe).sub.2 Cl ClII-241 2,4-Cl.sub.2 Me ClII-242 2,4-Cl.sub.2 OMe ClII-243 2,4-Cl.sub.2 Cl ClII-244 2,4-F.sub.2 Me ClII-245 2,4-F.sub.2 OMe ClII-246 2,4-F.sub.2 Cl ClII-247 3,4-Me.sub.2 Me ClII-251 3,4-Me.sub.2 OMe ClII-252 3,4-Me.sub.2 Cl ClII-253 3,4-Cl.sub.2 Me ClII-254 3,4-Cl.sub.2 OMe ClII-255 3,4-Cl.sub.2 Cl ClII-256 3,4-F.sub.2 Me ClII-257 3,4-F.sub.2 OMe ClII-261 3,4-F.sub.2 Cl Cl______________________________________
Among the compounds as shown in Table 2 (1/5 to 5/5), the 2-benzyloxy-4(or 6)-halogeno (or 4,6-dihalogeno)pyrimidine derivative of the formula (II-a) may be synthesized by substituting the moiety Z of the 2-(leaving-group-substituted)-4(or 6)-halogeno(or 4,6-dihalogeno)pyrimidine derivative of the formula (VIII) (Compound (VIII)) with the benzyl alcohol compound of the formula (IV) through nucleophilic displacement as shown in the Reaction scheme III. ##STR12## wherein R.sup.1 a, R.sup.2, X and n are as defined above; and Z represents a halogen, C.sub.1 -C.sub.4 alkylsulfonyl, C.sub.7 -C.sub.9 aralkylsulfonyl, or arylsulfonyl (usually containing C.sub.6 -C.sub.7, such as phenylsulfonyl and p-tolylsulfonyl).
The 2-benzyloxy-4(or 6)-halogeno-6(or 4)-(substituted thio)pyrimidine derivative of the formula (II-b1) is preferably synthesized by substituting a halogen of the 2-benzyloxy-4,6-dihalogenopyrimidine derivative of the formula (II-b2) with the thiol of the formula (X) through nucleophilic displacement in accordance with the Reaction scheme IV below. ##STR13## wherein R.sup.1 b represents C.sub.1 -C.sub.4 alkylthio or C.sub.1 -C.sub.4 haloalkylthio; and R.sup.2, X and n are as defined above.
Examples of Compound (VIII) which may be used as a starting material for Compound (II) are summarized in Table 3.
TABLE 3______________________________________No. R.sup.1 a R.sup.2 Z______________________________________VIII-1 H Cl MeSO.sub.2VIII-2 OCH.sub.2 CH.dbd.CH.sub.2 Cl MeSO.sub.2VIII-3 OCH.sub.2 CH.dbd.CMe.sub.2 Cl MeSO.sub.2VIII-4 Me Cl MeSO.sub.2VIII-5 Et Cl MeSO.sub.2VIII-6 t-Bu Cl MeSO.sub.2VIII-7 OMe Cl MeSO.sub.2VIII-8 H Cl ClVIII-9 Me Cl ClVIII-11 OEt Cl MeSO.sub.2VIII-12 OPr Cl MeSO.sub.2VIII-13 O-i-Pr Cl MeSO.sub.2VIII-14 OBu Cl MeSO.sub.2VIII-15 Ph Cl MeSO.sub.2VIII-16 CN Cl MeSO.sub.2VIII-17 CF.sub.3 Cl MeSO.sub.2VIII-21 OCH.sub.2 CF.sub.3 Cl MeSO.sub.2VIII-22 Br Br MeSO.sub.2VIII-23 Cl Cl MeSO.sub.2VIII-24 I I MeSO.sub.2VIII-25 Cl Cl Cl______________________________________
Among the 2-(leaving-group-substituted)pyrimidine derivative of the formula (VIII) as shown in Table 3, the 2-(substituted sulfonyl)pyrimidine derivative of the formula (IX) wherein Z is bonded to the pyrimidine ring by sulfonyl group may be synthesized by oxidizing sulfur of the 2-(substituted thio)pyrimidine derivative of the formula (VII) in accordance with the Reaction scheme V. ##STR14## wherein R.sup.1 a, R.sup.2, and R.sup.3 are as defined above.
Examples of an oxidizing agent which may be suitably used for the oxidation as shown above are peracids, sodium hypochlorite, chlorine, potassium permanganate, and sodium tungstate.
The peracid is preferably selected from peracetic acid, perbenzoic acid, m-chloroperbenzoic acid and perphthalic acid.
The peracetic acid may optionally be in situ produced in a reaction vessel by adding hydrogen peroxide to acetic acid solution of Compound (VII).
The oxidation is generally conducted in the presence of a solvent and the solvent which may be used includes halogenated alkyls (e.g., dichloromethane and chloroform), esters, aromatic hydrocarbons, lower fatty acids and water. Depending on the oxidizing agents (e.g., chlorine), water should be used.
This oxidation may be carried out at from a temperature of 5.degree. C. to the reflux point of the solvent (when a solvent is used).
More specifically, the oxidation may be conducted as described in the following:
Compounds (IX) (which are those corresponding to the Compounds Nos. VIII-1 to VIII-24 wherein Z represents MeSO.sub.2) each may be synthesized as follows:
0.1 mol of each of compounds of the corresponding number (Nos. VII-1 to VII-24 in Table 4) and 300 ml of chloroform are stirred while cooling with iced water, then 0.2 mol of m-chloroperbenzoic acid is added thereto. The resulting solution is stirred for 2 hours at a temperature of 15.degree. C. to 25.degree. C.
The reaction mixture is partitioned by using aqueous saturated sodium hydrogen carbonate, and the organic layer is washed with aqueous saturated sodium chloride, then dried over anhydrous sodium sulfate.
Thereafter, the solvent is distilled off to afford a crude product, which is then purified on column chromatography to obtain the corresponding Compound (IX).
Alternatively, each of Compound Nos. VII-1 to VII-24 in an acetic acid solution may be oxidized by adding hydrogen peroxide thereto so as to produce peracetic acid in a reaction vessel, whereby corresponding Compound (IX) can be obtained. In such cases, reaction may be conducted preferably for a period of 2 to 4 hours at a temperature of 60.degree. C. to 100.degree. C.
TABLE 4______________________________________No. R.sup.1 a R.sup.2 R.sup.3______________________________________VII-1 H Cl MeVII-2 OCH.sub.2 CH.dbd.CH.sub.2 Cl MeVII-3 OCH.sub.2 CH.dbd.CMe.sub.2 Cl MeVII-4 Me Cl MeVII-5 Et Cl MeVII-6 t-Bu Cl MeVII-7 OMe Cl MeVII-11 OEt Cl MeVII-12 OPr Cl MeVII-13 O-i-Pr Cl MeVII-14 OBu Cl MeVII-15 Ph Cl MeVII-16 CN Cl MeVII-17 CF.sub.3 Cl MeVII-21 OCH.sub.2 CF.sub.3 Cl MeVII-22 Br Br MeVII-23 Cl Cl MeVII-24 I I Me______________________________________
Among the 2-(substituted thio)pyrimidine derivative as shown in Table 4, 2-(substituted thio)-4,6-dihalogenopyrimidine derivatives can be synthesized by using the following process.
Process (a1): A malonic ester is cyclo-condensed with (S-substituted) isothiourea to obtain a 2-(substituted thio)-4,6-dihydroxypyrimidine derivative.
The same derivatives may be synthesized by the following process (a2) in place of the above process (a1).
Process (a2): A malonic ester is cyclo-condensed with thiourea to obtain 2-mercapto-4,6-dihydroxypyrimidine.
Then, the 2-mercapto group is converted to 2-(substituted thio) group in the presence of a basic compound. This process is suitable for the compound in which the substituent in the 2-(substituted thio) group is C.sub.1 -C.sub.4 alkyl or C.sub.7 -C.sub.9 aralkyl.
Each hydroxyl bonded to the positions 4 and 6 on the pyrimidine ring of the compound obtained by the process (a1) or (a2) is then converted to a halogen:
Process (b1): Hydroxyl is converted to a halogen by using phosphorus oxychloride (identical with phosphoryl chloride), phosphorus pentachloride, or phosphorus oxybromide (identical with phosphoryl bromide).
Further, chlorine at the position 4 and/or 6 may be converted to iodine through nucleophilic displacement by using potassium iodide or aqueous concentrated hydroiodic acid.
Compounds in which a substituent is ether-bonded to the position 4 and/or 6 on the pyrimidine ring can be synthesized as follows:
Process (c1): A halogen at the position 4 or 6 on the pyrimidine ring of the compound which is obtained from the process (b1) is etherified through nucleophilic displacement in the presence of a basic compound.
Process (d1): Either one of halogens at the positions 4 and 6 on the pyrimidine ring of the compound which is obtained from the process (b1) is converted to hydroxyl. Process (e1): Hydroxyl of the compound which is obtained from the process (d1) is etherified.
Among the 2-(substituted thio)pyrimidine derivatives of the formula (VII), those in which R.sup.1 represents a substituent linked by carbon-carbon bond or hydrogen, and R.sup.2 represents a halogen can be synthesized as follows:
Process (a3): A compound containing a 1,3-dicarbonyl group {one of the carbonyl groups is derived from carboxylic ester and the other is derived from formyl group (or acetal thereof) or acyl group (or ketal thereof)} may be cyclo-condensed with a (S-substituted) thiourea to obtain a 2-(substituted thio)-4(or 6)-hydroxypyrimidine derivative.
The same derivatives may be synthesized by the following process (a4) in place of the above process (a3).
Process (a4): A compound containing a 1,3-dicarbonyl group {one of the carbonyl groups is derived from carboxylic ester and the other is derived from formyl group (or acetal thereof) or acyl group (or ketal thereof)} may be cyclo-condensed with thiourea to obtain a 2-mercapto-4-(or 6)-hydroxypyrimidine derivative.
Then, 2-mercapto group is converted to 2-(substituted thio) group in the presence of a basic compound.
This process is suitable for the compounds in which the substituent in the 2-(substituted thio) group is C.sub.1 -C.sub.4 alkyl or C.sub.7 -C.sub.9 aralkyl.
Then, hydroxyl bonded to the position 4 or 6 on the pyrimidine ring of the compound obtained by the process (a3) or (a4) may be converted to a halogen:
Process (b2): Hydroxyl may be converted to a halogen by using phosphorus oxychloride (identical with phosphoryl chloride), phosphorus pentachloride, or phosphorus oxybromide (identical with phosphoryl bromide).
Synthesis processes may be more specifically described in the following.
Compounds which contain on the pyrimidine ring thereof, hydroxyl to be afterwards converted to chlorine or bromine and which are usable as starting materials for the production of Compound NOs. VII-1, VII-4, VII-5, VII-6, VII-15, VII-17, VII-22 and VII-23 can be synthesized by using the synthesis processes (a1) or (a3) in a manner described in the section (1) or section (2) below.
(1) 0.1 mol of methyl acetoacetate or methyl trifluoroacetoacetate, 0.1 mol of methylisothiourea sulfate (2-methyl-2-thiopseudourea sulfate) and 0.1 mol of sodium methoxide are reacted with one another in 500 ml of methyl alcohol at room temperature for overnight.
Then, the reaction mixture is cooled with iced water and 0.1 mol of hydrochloric acid is added thereto.
After insoluble matter is filtered off, the solvent is distilled off from the filtrate to afford a crude product, which may be then recrystallized to obtain a purified product.
(2) 0.1 mol of ethyl 3,3-diethoxypropionate, ethyl acetoacetate, ethyl propionylacetate, ethyl 2,2-dimethylpropionylacetate, ethyl benzoylacetate, ethyl trifluoroacetoacetate or diethyl malonate, 0.1 mol of methylisothiourea sulfate (2-methyl-2-thiopseudourea sulfate) and 0.1 mol of sodium ethoxide are reacted with one another in 500 ml of ethyl alcohol at reflux point for 4 hours.
The reaction mixture is allowed to cool to room temperature, and then, while further cooling with iced water, 0.1 mol of hydrochloric acid is added thereto.
After insoluble matter is filtered off, the solvent is distilled off from the filtrate to afford a crude product, which may be then recrystallized to obtain a purified product.
Each of the Compound Nos. VII-22 and VII-23 can be synthesized by using the process (b1).
50 ml of phosphorus oxychloride (identical with phosphoryl chloride) or phosphorus oxybromide (identical with phosphoryl bromide) is reacted with 0.1 mol of 4,6-dihydroxy-2-methylthiopyrimidine while stirring at a temperature of 70.degree. C. to 80.degree. C. for 7 hours.
Excess phosphorus oxychloride or phosphorus oxybromide is distilled off under reduced pressure from the reaction mixture.
The residue is redissolved in chloroform and washed successively with aqueous sodium hydrogen carbonate and water. After dried over sodium sulfate, the solvent is distilled off to afford a crude product, which may be then purified on column chromatography to obtain a purified product.
Compound No. VII-24 can be synthesized by heating the Compound No. VII-23 at about 70.degree. C. for about 13 hours in the presence of an excessive amount of aqueous 57% hydroiodic acid.
Each of the Compounds Nos. VII-1, VII-4 to VII-6, VII-15 and VII-17 can be synthesized by using the process (b2).
0.1 mol of a compound containing on the pyrimidine ring hydroxyl to be afterwards converted to chlorine is reacted with 50 ml of phosphorus oxychloride while stirring at a temperature of 70.degree. C. to 80.degree. C. for 7 hours.
Excess phosphorus oxychloride is distilled off under reduced pressure from the reaction mixture.
The residue is redissolved in chloroform and washed successively with aqueous sodium hydrogen carbonate and water. After dried over sodium sulfate, the solvent is distilled off to afford a crude product, which may be then purified on column chromatography to obtain a purified product.
Each of the Compound Nos. VII-2, VII-3, VII-7, VII-11 to VII-14 and VII-21 can be synthesized by using the process (c1).
Compound Nos. VII-2 and VII-3 are prepared by nucleophilic substitution of one chlorine of Compound No. VII-23 with equimolar amounts of sodium 2-propenoxide and sodium 3-methyl-2-buten-1-oxide, respectively, in dimethylformamide at room temperature for overnight.
Compound Nos. VII-7 and VII-11 are prepared by nucleophilic substitution of one chlorine of Compound No. VII-23 with equimolar amounts of sodiumu methoxide and sodium ethoxide, respectively, in tetrahydrofuran at room temperature for 30 minites.
Compound Nos. VII-12 to VII-14 and VII-21 are prepared by nucleophilic substitution of one chlorine of Compound No. VII-23 with equimolar amounts of sodium propoxide, sodium butoxide, sodium 1-methylethoxide and sodium 2,2,2-trifluoroethoxide, respectively, in the corresponding alcohol at a temperature of 35.degree. C. to 45.degree. C. for 4 hours.
After the solvent and alcohol are distilled off from the reaction mixture under reduced pressure, ether is poured into the residue, and the mixture is washed with water and then dried over sodium sulfate.
Ether is distilled off to afford a crude product, which may then be purified on column chromatography to obtain a purified product.
Reaction temperature, reaction time and amounts of starting materials can be changed within the extent as described in the section (1) of the Reference synthesis example 1 set forth below.
Examples of the 2-(substituted sulfonyl)-4-phenoxypyrimidine derivative of the formula (V) useful as a starting material for the above reaction scheme II are shown in Table 5 (1/12 to 12/12).
TABLE 5______________________________________NO. (Ya).sub.m R.sup.1 a R.sup.3______________________________________V-1 H H MeV-2 H OCH.sub.2 CH.dbd.CH.sub.2 MeV-3 H OCH.sub.2 CH.dbd.CMe.sub.2 MeV-4 H Me MeV-5 H Et MeV-6 H t-Bu MeV-7 H OMe MeV-11 H OEt MeV-12 H OPr MeV-13 H O-i-Pr MeV-14 H OBu MeV-15 H Ph MeV-16 H CN MeV-17 H CF.sub.3 MeV-21 H OCH.sub.2 CF.sub.3 MeV-22 H Br MeV-23 H Cl MeV-24 H I MeV-25 2-Me H MeV-26 2-Me OCH.sub.2 CH.dbd.CH.sub.2 MeV-27 2-Me OCH.sub.2 CH.dbd.CMe.sub.2 MeV-31 2-Me Me MeV-32 2-Me Et MeV-33 2-Me t-Bu MeV-34 2-Me OMe MeV-35 2-Me OEt MeV-36 2-Me OPr MeV-37 2-Me O-i-Pr MeV-41 2-Me OBu MeV-42 2-Me Ph MeV-43 2-Me CN MeV-44 2-Me CF.sub.3 MeV-45 2-Me OCH.sub.2 CF.sub.3 MeV-46 2-Me Br MeV-47 2-Me Cl MeV-51 2-Me I MeV-52 2-OMe H MeV-53 2-OMe OCH.sub.2 CH.dbd.CH.sub.2 MeV-54 2-OMe OCH.sub.2 CH.dbd.CMe.sub.2 MeV-55 2-OMe Me MeV-56 2-OMe Et MeV-57 2-OMe t-Bu MeV-61 2-OMe OMe MeV-62 2-OMe OEt MeV-63 2-OMe OPr MeV-64 2-OMe O-i-Pr MeV-65 2-OMe OBu MeV-66 2-OMe Ph MeV-67 2-OMe CN MeV-71 2-OMe CF.sub.3 MeV-72 2-OMe OCH.sub.2 CF.sub.3 MeV-73 2-OMe Br MeV-74 2-OMe Cl MeV-75 2-OMe I MeV-76 2-CF.sub.3 H MeV-77 2-CF.sub.3 OCH.sub.2 CH.dbd.CH.sub.2 MeV-81 2-CF.sub.3 OCH.sub.2 CH.dbd.CMe.sub.2 MeV-82 2-CF.sub.3 Me MeV-83 2-CF.sub.3 Et MeV-84 2-CF.sub.3 t-Bu MeV-85 2-CF OMe MeV-86 2-CF.sub.3 OEt MeV-87 2-CF.sub.3 OPr MeV-91 2-CF.sub.3 O-i-Pr MeV-92 2-CF.sub.3 OBu MeV-93 2-CF.sub.3 Ph MeV-94 2-CF.sub.3 CN MeV-95 2-CF.sub.3 CF.sub.3 MeV-96 2-CF.sub.3 OCH.sub.2 CF.sub.3 MeV-97 2-CF.sub.3 Br MeV-101 2-CF.sub.3 Cl MeV-102 2-CF.sub.3 I MeV-103 2-Br H MeV-104 2-Br OCH.sub.2 CH.dbd.CH.sub.2 MeV-105 2-Br OCH.sub.2 CH.dbd.CMe.sub.2 MeV-106 2-Br Me MeV-107 2-Br Et MeV-111 2-Br t-Bu MeV-112 2-Br OMe MeV-113 2-Br OEt MeV-114 2-Br OPr MeV-115 2-Br O-i-Pr MeV-116 2-Br OBu MeV-117 2-Br Ph MeV-121 2-Br CN MeV-122 2-Br CF.sub.3 MeV-123 2-Br OCH.sub.2 CF.sub.3 MeV-124 2-Br Br MeV-125 2-Br Cl MeV-126 2-Br I MeV-127 2-Cl H MeV-131 2-Cl OCH.sub.2 CH.dbd.CH.sub.2 MeV-132 2-Cl OCH.sub.2 CH.dbd.CMe.sub.2 MeV-133 2-Cl Me MeV-134 2-Cl Et MeV-135 2-Cl t-Bu MeV-136 2-Cl OMe MeV-137 2-Cl OEt MeV-141 2-Cl OPr MeV-142 2-Cl O-i-Pr MeV-143 2-Cl OBu MeV-144 2-Cl Ph MeV-145 2-Cl CN MeV-146 2-Cl CF.sub.3 MeV-147 2-Cl OCH.sub.2 CF.sub.3 MeV-151 2-Cl Br MeV-152 2-Cl Cl MeV-153 2-Cl I MeV-154 2-F H MeV-155 2-F OCH.sub.2 CH.dbd.CH.sub.2 MeV-156 2-F OCH.sub.2 CH.dbd.CMe.sub.2 MeV-157 2-F Me MeV-161 2-F Et MeV-162 2-F t-Bu MeV-163 2-F OMe MeV-164 2-F OEt MeV-165 2-F OPr MeV-166 2-F O-i-Pr MeV-167 2-F OBu MeV-171 2-F Ph MeV-172 2-F CN MeV-173 2-F CF.sub.3 MeV-174 2-F OCH.sub.2 CF.sub.3 MeV-175 2-F Br MeV-176 2-F Cl MeV-177 2-F I MeV-181 3-Me H MeV-182 3-Me OCH.sub.2 CH.dbd.CH.sub.2 MeV-183 3-Me OCH.sub.2 CH.dbd.CMe.sub.2 MeV-184 3-Me Me MeV-185 3-Me Et MeV-186 3-Me t-Bu MeV-187 3-Me OMe MeV-191 3-Me OEt MeV-192 3-Me OPr MeV-193 3-Me O-i-Pr MeV-194 3-Me OBu MeV-195 3-Me Ph MeV-196 3-Me CN MeV-197 3-Me CF.sub.3 MeV-201 3-Me OCH.sub.2 CF.sub.3 MeV-202 3-Me Br MeV-203 3-Me Cl MeV-204 3-Me I MeV-205 3-OMe H MeV-206 3-OMe OCH.sub.2 CH.dbd.CH.sub.2 MeV-207 3-OMe OCH.sub.2 CH.dbd.CMe.sub.2 MeV-211 3-OMe Me MeY-212 3-OMe Et MeV-213 3-OMe t-Bu MeV-214 3-OMe OMe MeV-215 3-OMe OEt MeV-216 3-OMe OPr MeV-217 3-OMe O-i-Pr MeV-221 3-OMe OBu MeV-222 3-OMe Ph MeV-223 3-OMe CN MeV-224 3-OMe CF.sub.3 MeV-225 3-OMe OCH.sub.2 CF.sub.3 MeV-226 3-OMe Br MeV-227 3-OMe Cl MeV-231 3-OMe I MeV-232 3-CF.sub.3 H MeV-233 3-CF.sub.3 OCH.sub.2 CH.dbd.CH.sub.2 MeV-234 3-CF.sub.3 OCH.sub.2 CH.dbd.CMe.sub.2 MeV-235 3-CF.sub.3 Me MeV-236 3-CF.sub.3 Et MeV-237 3-CF.sub.3 t-Bu MeV-241 3-CF.sub.3 OMe MeV-242 3-CF.sub.3 OEt MeV-243 3-CF.sub.3 OPr MeV-244 3-CF.sub.3 O-i-Pr MeV-245 3-CF.sub.3 OBu MeV-246 3-CF.sub.3 Ph MeV-247 3-CF.sub.3 CN MeV-251 3-CF.sub.3 CF.sub.3 MeV-252 3-CF.sub.3 OCH.sub.2 CF.sub.3 MeV-253 3-CF.sub.3 Br MeV-254 3-CF.sub.3 Cl MeV-255 3-CF.sub.3 I MeV-256 3-OCF.sub.3 H MeV-257 3-OCF.sub.3 OCH.sub.2 CH.dbd.CH.sub.2 MeV-261 3-OCF.sub.3 OCH.sub.2 CH.dbd.CMe.sub.2 MeV-262 3-OCF.sub.3 Me MeV-263 3-OCF.sub.3 Et MeV-264 3-OCF.sub.3 t-Bu MeV-265 3-OCF.sub.3 OMe MeV-266 3-OCF.sub.3 OEt MeV-267 3-OCF.sub.3 OPr MeV-271 3-OCF.sub.3 O-i-Pr MeV-272 3-OCF.sub.3 OBu MeV-273 3-OCF.sub.3 Fh MeV-274 3-OCF.sub.3 CN MeV-275 3-OCF.sub.3 CF.sub.3 MeV-276 3-OCF.sub.3 OCH.sub.2 CF.sub.3 MeV-277 3-OCF.sub.3 Br MeV-281 3-OCF.sub.3 Cl MeV-282 3-OCF.sub.3 I MeV-283 3-Br H MeV-284 3-Br OCH.sub.2 CH.dbd.CH.sub.2 MeV-285 3-Br OCH.sub.2 CH.dbd.CMe.sub.2 MeV-286 3-Br Me MeV-287 3-Br Et MeV-291 3-Br t-Bu MeV-292 3-Br OMe MeV-293 3-Br OEt MeV-294 3-Br OPr MeV-295 3-Br O-i-Pr MeV-296 3-Br OBu MeV-297 3-Br Ph MeV-301 3-Br CN MeV-302 3-Br CF.sub.3 MeV-303 3-Br OCH.sub.2 CF.sub.3 MeV-304 3-Br Br MeV-305 3-Br Cl MeV-306 3-Br I MeV-307 3-Cl H MeV-311 3-Cl OCH.sub.2 CH.dbd.CH.sub.2 MeV-312 3-Cl OCH.sub.2 CH.dbd.CMe.sub.2 MeV-313 3-Cl Me MeV-314 3-Cl Et MeV-315 3-Cl t-Bu MeV-316 3-Cl OMe MeV-317 3-Cl OEt MeV-321 3-Cl OPr MeV-322 3-Cl O-i-Fr MeV-323 3-Cl OBu MeV-324 3-Cl Ph MeV-325 3-Cl CN MeV-326 3-Cl CF.sub.3 MeV-327 3-Cl OCH.sub.2 CF.sub.3 MeV-331 3-Cl Br MeV-332 3-Cl Cl MeV-333 3-Cl I MeV-334 3-F H MeV-335 3-F OCH.sub.2 CH.dbd.CH.sub.2 MeV-336 3-F OCH.sub.2 CH.dbd.CMe.sub.2 MeV-337 3-F Me MeV-341 3-F Et MeV-342 3-F t-Bu MeV-343 3-F OMe MeV-344 3-F OEt MeV-345 3-F OPr MeV-346 3-F O-i-Pr MeV-347 3-F OBu MeV-351 3-F Ph MeV-352 3-F CN MeV-353 3-F CF.sub.3 MeV-354 3-F OCH.sub.2 CF.sub.3 MeV-355 3-F Br MeV-356 3-F Cl MeV-357 3-F I MeV-361 3-I H MeV-362 3-I OCH.sub.2 CH.dbd.CH.sub.2 MeV-363 3-I OCH.sub.2 CH.dbd.OMe.sub.2 MeV-364 3-I Me MeV-365 3-I Et MeV-366 3-I t-Bu MeV-367 3-I OMe MeV-371 3-I OEt MeV-372 3-I OPr MeV-373 3-I O-i-Pr MeV-374 3-I OBu MeV-375 3-I Ph MeV-376 3-I CN MeV-377 3-I CF.sub.3 MeV-381 3-I OCH.sub.2 CF.sub.3 MeV-382 3-I Br MeV-383 3-I Cl MeV-384 3-I I MeV-385 4-Me H MeV-386 4-Me OCH.sub.2 CH.dbd.CH.sub.2 MeV-387 4-Me OCH.sub.2 CH.dbd.CMe.sub.2 MeV-391 4-Me Me MeV-392 4-Me Et MeV-393 4-Me t-Bu MeV-394 4-Me OMe MeV-395 4-Me OEt MeV-396 4-Me OPr MeV-397 4-Me O-i-Pr MeV-401 4-Me OBu MeV-402 4-Me Ph MeV-403 4-Me CN MeV-404 4-Me CF.sub.3 MeV-405 4-Me OCH.sub.2 CF.sub.3 MeV-406 4-Me Br MeV-407 4-Me Cl MeV-411 4-Me I MeV-412 4-OMe H MeV-413 4-OMe OCH.sub.2 CH.dbd.CH.sub.2 MeV-414 4-OMe OCH.sub.2 CH.dbd.CMe.sub.2 MeV-415 4-OMe Me MeV-416 4-OMe Et MeV-417 4-OMe t-Bu MeV-421 4-OMe OMe MeV-422 4-OMe OEt MeV-423 4-OMe OPr MeV-424 4-OMe O-i-Pr MeV-425 4-OMe OBu MeV-426 4-OMe Ph MeV-427 4-OMe CN MeV-431 4-OMe CF.sub.3 MeV-432 4-OMe OCH.sub.2 CF.sub.3 MeV-433 4-OMe Br MeV-434 4-OMe Cl MeV-435 4-OMe I MeV-436 4-CF.sub.3 H MeV-437 4-CF.sub.3 OCH.sub.2 CH.dbd.CH.sub.2 MeV-441 4-CF.sub.3 OCH.sub.2 CH.dbd.CMe.sub.2 MeV-442 4-CF.sub.3 Me MeV-443 4-CF.sub.3 Et MeV-444 4-CF.sub.3 t-Bu MeV-445 4-CF.sub.3 OMe MeV-446 4-CF.sub.3 OEt MeV-447 4-CF.sub.3 OPr MeV-451 4-CF.sub.3 O-i-Pr MeV-452 4-CF.sub.3 OBu MeV-453 4-CF.sub.3 Ph MeV-454 4-CF.sub.3 CN MeV-455 4-CF.sub.3 CF.sub.3 MeV-456 4-CF.sub.3 OCH.sub.2 CF.sub.3 MeV-457 4-CF.sub.3 Br MeV-461 4-CF.sub.3 Cl MeV-462 4-CF.sub.3 I MeV-463 4-OCF.sub.3 H MeV-464 4-OCF.sub.3 OCH.sub.2 CH.dbd.CH.sub.2 MeV-465 4-OCF.sub.3 OCH.sub.2 CH.dbd.CMe.sub.2 MeV-466 4-OCF.sub.3 Me MeV-467 4-OCF.sub.3 Et MeV-471 4-OCF.sub.3 t-Bu MeV-472 4-OCF.sub.3 OMe MeV-473 4-OCF.sub.3 OEt MeV-474 4-OCF.sub.3 OPr MeV-475 4-OCF.sub.3 O-i-Pr MeV-476 4-OCF.sub.3 OBu MeV-477 4-OCF.sub.3 Ph MeV-481 4-OCF.sub.3 CN MeV-482 4-OCF.sub.3 CF.sub.3 MeV-483 4-OCF.sub.3 OCH.sub.2 CF.sub.3 MeV-484 4-OCF.sub.3 Br MeV-485 4-OCF.sub.3 Cl MeV-486 4-OCF.sub.3 I MeV-487 4-Br H MeV-491 4-Br OCH.sub.2 CH.dbd.CH.sub.2 MeV-492 4-Br OCH.sub.2 CH.dbd.CMe.sub.2 MeV-493 4-Br Me MeV-494 4-Br Et MeV-495 4-Br t-Bu MeV-496 4-Br OMe MeV-497 4-Br OEt MeV-501 4-Br OPr MeV-502 4-Br O-i-Pr MeV-503 4-Br OBu MeV-504 4-Br Ph MeV-505 4-Br CN MeV-506 4-Br CF.sub.3 MeV-507 4-Br OCH.sub.2 CF.sub.3 MeV-511 4-Br Br MeV-512 4-Br Cl MeV-513 4-Br I MeV-514 4-Cl H MeV-515 4-Cl OCH.sub.2 CH.dbd.CH.sub.2 MeV-516 4-Cl OCH.sub.2 CH.dbd.CMe.sub.2 MeV-517 4-Cl Me MeV-521 4-Cl Et MeV-522 4-Cl t-Bu MeV-523 4-Cl OMe MeV-524 4-Cl bEt MeV-525 4-Cl OPr MeV-526 4-Cl O-i-Pr MeV-527 4-Cl OBu MeV-531 4-Cl Ph MeV-532 4-Cl CN MeV-533 4-Cl CF.sub.3 MeV-534 4-Cl OCH.sub.2 CE3 MeV-535 4-Cl Br MeV-536 4-Cl Cl MeV-537 4-Cl I MeV-541 4-F H MeV-542 4-F OCH.sub.2 CH.dbd.CH.sub.2 MeV-543 4-F OCH.sub.2 CH.dbd.CMe.sub.2 MeV-544 4-F Me MeV-545 4-F Et MeV-546 4-F t-Bu MeV-547 4-F OMe MeV-551 4-F OEt MeV-552 4-F OPr MeV-553 4-F O-i-Pr MeV-554 4-F OBu MeV-555 4-F Fh MeV-556 4-F CN MeV-557 4-F CF.sub.3 MeV-561 4-F OCH.sub.2 CF.sub.3 MeV-562 4-F Br MeV-563 4-F Cl MeV-564 4-F I MeV-565 4-I H MeV-566 4-I OCH.sub.2 CH.dbd.CH.sub.2 MeV-567 4-I OCH.sub.2 CH.dbd.CMe.sub.2 MeV-571 4-I Me MeV-572 4-I Et MeV-573 4-I t-Bu MeV-574 4-I OMe MeV-575 4-I OEt MeV-576 4-I OPr MeV-577 4-I O-i-Pr MeV-581 4-I OBu MeV-582 4-I Ph MeV-583 4-I CN MeV-584 4-I CF.sub.3 MeV-585 4-I OCH.sub.2 CF.sub.3 MeV-586 4-I Br MeV-587 4-I Cl MeV-591 4-I I Me______________________________________
As shown by the following Reaction scheme VI, the 2-(substituted sulfonyl)-4-phenoxypyrimidine derivative of the formula (V) can be synthesized by oxidizing sulfur of the 2-(substituted thio)-4-phenoxypyrimidine derivative of the formula (VI). ##STR15## wherein R.sup.1 a, R.sup.3, Ya and m are as defined above.
This oxidation may be conducted under the same reaction conditions (solvent, oxidizing reagent, temperature and reaction time) as those described about the Reaction scheme V by which sulfur of the 2-(substituted thio)pyrimidine derivative of the formula (VII) is oxidized to obtain the 2-(substituted sulfonyl)pyrimidine derivative of the formula (IX).
The 2-(substituted thio)-4-phenoxypyrimidine derivative of the formula (VI) useful as a starting material for the above oxidation can be synthesized by substituting a halogen at the position 4 or 6 of the 2-(substituted)pyrimidine derivative of the formula (VII) with a phenol compound of the formula (III-a) through nucleophilic displacement, as shown in the following Reaction scheme VII. ##STR16## wherein R.sup.1 a, R.sup.2, R.sup.3, Ya and m are as defined above.
The above-mentioned nucleophilic displacement on the pyrimidine ring (Reaction schemes III, IV and VII) can be conducted under the same reaction conditions (used base, solvent, temperature and reaction time) as those described about the Reaction scheme I and II.
The 2-benzyloxy-4-phenoxypyrimidine derivative represented by the above formula (I) of the present invention (hereinafter referred to as "compound of the present invention") exhibits reliable herbicidal activity at a low application dose and shows good selectivity between crops and weeds. Thus, a herbicidal composition containing the compound as an active ingredient may suitably be used in pre- or post-emergence weed control treatment for protecting important crops such as wheat, rice, corn, soybean, cotton, beet, potato, tomato or the like from weeds irrespective of dicotyledons and monocotyledons.
Examples of dicotyledonous weeds which could be controlled by the application of the herbicidal composition of the present invention are genera Amaranthus, Bidens, Stellaria, Abutilon, Convolvulus, Matricaria, Galium, Lindernia, and the like.
Examples of monocotyledonous weeds include genera Echinochloa, Setaria, Digitaria, Avena, Cyperus, Alisma, Monochoria, and the like.
Application sites of the herbicidal composition of the present invention may be not only agricultural lands such as upland fields, paddy fields and orchards but also nonagricultural lands such as athletic fields and factory sites.
The compound of the present invention may also be applied for producing ornamental products resembling to dried flowers, since spraying the compounds of the present invention to the foliage may result whitening thereof.
Although the compound of the present invention may be applied as it is, they are generally applied after formulated with an adjuvant into various forms of compositions such as powders, wettable powders, granules, or emulsifiable concentrates.
The composition is usually formulated in such a way that it contains one or more of the compounds of the present invention at an amount of 0.1 to 95% by weight, preferably 0.5 to 90% by weight, more preferably 2 to 70% by weight.
Among adjuvants including carriers, diluents and surface active agents, suitable solid carriers are talc, kaolin, bentonite, diatomaceous earth, white carbon, clay, and the like. Suitable liquid diluents are water, xylene, toluene, chlorobenzene, cyclohexane, cyclohexanone, dimethylsulfoxide, dimethylformamide, alcohol, and the like.
Surface active agents may be properly selected depending upon their effects, and suitable emulsifying agents include polyoxyethylene alkylaryl ether, polyoxyethylene sorbitan monolaurate, and the like. Suitable dispersing agents include lignin sulfonate, dibutylnaphthalene sulfonate, and the like. Suitable wetting agents are alkyl sulfonates, alkylphenyl sulfonates, and the like.
The above mentioned compositions include those which are to be applied as such and those which are to be applied after diluted to a proper concentration by using diluents such as water. When applied in a diluted form, the compound of the present invention is contained preferably at a concentration of 0.001 to 1.0% by weight. Application dose of the compounds of the present invention is 0.01 to 10 kg/ha, preferably 0.05 to 5 kg/ha.
The concentrations and application doses defined above are varied depending on dosage forms, time of application, way of application, application sites, plants to be treated, and the like. Thus, modifications thereof are possible without limited to the above defined range. Further, the compounds of the present invention may be used in combination with other active ingredients such as fungicides, insecticides, acaricides and herbicides.

EXAMPLES
The 2-benzyloxy-4-phenoxypyrimidine derivative of the present invention, production processes and use thereof will be more specifically described by way of the following synthesis examples, formulation examples and test examples.
It should be also understood that the present invention are not limited to these examples without departing from the scopes thereof.
The abbreviations employed in the synthesis examples and reference synthesis examples are as follows:
DMF: dimethylformamide
NaH: sodium hydride
THF: tetrahydrofuran
KI: potassium iodide
m-CPBA: m-chloroperbenzoic acid
Synthesis Example 1
Synthesis of 4-methyl-6-phenoxy-2-(phenylmethoxy)pyrimidine (Compound No. I-4)
Benzyl alcohol (0.29 g, 0.0013.times.2.0 mol) was dissolved in THF (20 ml), then NaH (0.07 g (60%), 0.0013.times.1.2 mol) was added thereto. When the evolution of hydrogen stopped, 4-methyl-2-methylsulfonyl-6-phenoxypyrimidine (Compound No. V-4) (0.35 g, 0.0013 mol) which had been synthesized as described in Reference synthesis example 8 below was added thereto and the mixture was allowed to react for about 2 hours at room temperature. The reaction solution was poured into water, extracted with ethyl acetate. Thereafter, the organic layer was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, then purified on silica gel column to obtain the end product. Yield: 0.29 g (79%).
Synthesis Example 2
Synthesis of 4-methyl-6-(3-methylphenoxy)-2-(phenylmethoxy)pyrimidine (Compound No. I-214)
The end product was obtained in a similar manner to Synthesis example 1, by starting from m-cresol (0.35 g, 0.0017.times.2.0 mol) and 4-chloro-6-methyl-2-(phenylmethoxy)-pyrimidine (Compound No. II-4) (0.40 g, 0.0017 mol) which had been synthesized as described in Reference synthesis example 3 below.
Yield: 0.55 g (100%).
Synthesis Example 3
Synthesis of 2-phenylmethoxy-4-(2-propenyloxy)-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. I-302)
The end product was obtained in a similar manner to Synthesis example 1, by starting from benzyl alcohol (0.16 g, 0.00134.times.1.1 mol) and 2-methylsulfonyl-4-(2-propenyloxy)-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. V-233) (0.50 g, 0.00134 mol).
Yield: 0.18 g (31%).
Synthesis Example 4
Synthesis of 4-methyl-2-phenylmethoxy-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. I-304)
The end product was obtained in a similar manner to Synthesis example 1, by starting from benzyl alcohol (0.23 g, 0.00105.times.2.0 mol) and 4-methyl-2-methylsulfonyl-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. V-235) (0.35 g, 0.00105 mol).
Yield: 0.21 g (54%).
Synthesis Example 5
Synthesis of 4-methoxy-2-phenylmethoxy-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. I-307)
The end product was obtained in a similar manner to Synthesis example 1, by starting from benzyl alcohol (0.155 g, 0.00144.times.1.0 mol) and 4-methoxy-2-methylsulfonyl-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. V-241)(0.50 g, 0.00144 mol).
Yield: 0.21 g (39%).
Synthesis Example 6
Synthesis of 4-methylthio-2-phenylmethoxy-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. I-315)
Aqueous sodium thiomethoxide (15%, 2.75 g, 0.0059.times.1.0 mol) was added dropwise in 4,6-dichloro-2-(phenylmethoxy)pyrimidine (Compound No. II-26) (1.5 g, 0.0059 mol) dissolved in THF at room temperature. After allowed to react for 2 hours, the reaction solution was partitioned between ethyl acetate and aqueous saturated sodium hydrogen carbonate. The organic layer was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, then purified on a silica gel column to obtain 4-chloro-6-methylthio-2-(phenylmethoxy)pyrimidine (Compound No. II-15) as an intermediate.
Thus obtained intermediate was dissolved in DMF, thereafter a THF/DMF solution containing 3-(trifluoromethyl)phenol (0.95 g, 0.0059.times.1.0 mol), NaH (0.24 g (ca. 60% in mineral oil), 0.0059.times.1.0 mol), and KI (0.45 g, 0.0059.times.0.5 mol) was added thereto, and the resulting solution was refluxed for about 7 hours. The reaction solution was partitioned between ethyl acetate and aqueous saturated sodium hydrogen carbonate. The organic layer was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, then purified on a silica gel column to obtain the end product.
Yield: 2.0 g (88.0%).
Synthesis Example 7
Synthesis of 4-ethylthio-2-phenylmethoxy-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. I-316)
The end product was obtained in a similar manner to Synthesis example 1, by starting from 3-(trifluoromethyl)-phenol (0.35 g, 0.00142.times.1.5 mol) and 4-chloro-6-ethylthio-2-(phenylmethoxy)pyrimidine (Compound No. II-16) (0.40 g, 0.00142 mol) which had been synthesized as described in Reference synthesis example 5.
Yield: 0.49 g (85%).
Synthesis Example 8
Synthesis of 4-bromo-2-phenylmethoxy-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. I-325)
An alkoxide was prepared from benzyl alcohol (0.40 g, 0.0025.times.1.5 mol) and NaH (0.106 g (ca. 60% in mineral oil), 0.00252.times.1.05 mol) in THF.
4-Bromo-2-methylsulfonyl-6-�3-(trifluoromethyl)-phenyl!pyrimidine (Compound No. V-253) (1.0 g, 0.00252 mol) was added thereto and the resulting solution was stirred for about 2 hours at room temperature. Thereafter, the reaction solution was partitioned between ethyl acetate and aqueous saturated sodium hydrogen carbonate. The organic layer was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, then purified on a silica gel column to obtain an oily product.
Yield: 0.30 g (37%).
Synthesis Example 9
Synthesis of 4-chloro-2-phenylmethoxy-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. I-326)
The end product was obtained in a similar manner to Synthesis example 1, by starting from 3-(trifluoromethyl)-phenol (0.35 g, 0.0020.times.2.0 mol) and 4,6-dichloro-2-(phenylmethoxy)pyrimidine (Compound No. II-26)(0.50 g, 0.0020 mol).
Yield: 0.60 g (80%).
Synthesis Example 10
Synthesis of 4-iodo-2-phenylmethoxy-6-�3-(trifluoromethyl)-phenoxy!pyrimidine (Compound No. I-327)
The end product was obtained in a similar manner to Synthesis example 1, by starting from benzyl alcohol (0.22 g, 0.0018.times.1.1 mol) and 4-iodo-2-methylsulfonyl-6-�3-(trifluoromethyl) phenoxy!pyrimidine (Compound No. V-255) (0.8 g, 0. 0018 mol).
Yield: 0.63 g (74%).
Physicochemical properties of the compounds of the Synthesis examples 1 to 10 and other compounds synthesized in a similar manner to Synthesis example 1 are shown in Table 6 below.
TABLE 6______________________________________ Property orNo. m.p. (.degree.C.) .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.)______________________________________I-4 87-88 2.34(3H, s), 5.18(2H, s), 6.21(1H, s), 6.8-7.6(10H, m)I-214 oily 2.34(6H, s), 5.20(2H, s), 6.17(1H, s), 6.6-7.5(4H, m), 7.21(5H, s)I-301 52-54 5.17(2H, s), 6.46(1H, d, J = 5.5Hz), 7.20(5H,s), 7.2-7.7(4H, complex), 8.27(1H, d, J = 5.5Hz)I-302 93-94 4.6-4.9(2H, m), 5.0-5.5(2H, m), 5.16(2H, s) 5.5-6.2(1H, m), 5.77(1H, s), 7.20(5H, s), 7.2-7.6(4H, m)I-304 oily 2.37(3H, s), 5.11(2H, s), 6.27(1H, s), 7.0-7.7(4H, m), 7.16(5H, s)I-307 oily 3.85(3H, s), 5.13(2H, s), 5.73(1H, s), 7.1-7.6(4H, m), 7.17(5H, s)I-311 oily 1.30(3H, t, J = 6.9Hz), 4.28(2H, q, J = 6.9Hz), 5.11(2H, s), 5.67(1H, s), 7.0-7.5(4H, m), 7.14(5H, s)I-315 57-60 2.49(3H, s), 5.19(2H, s), 6.32(1H, s), 7.0-7.6(4H, m), 7.22(5H, s)I-316 oily 1.30(3H, t, J = 6.9Hz), 3.07(2H, q, J = 6.9Hz), 5.17(2H, s), 6.26(1H, s), 7.0-7.6(4H, m), 7.20(5H, s)I-325 oily 5.16(2H, s), 6.68(1H, s), 7.1-7.6(4H, m), 7.20(5H, s)I-326 91-93 5.12(2H, s), 6.46(1H, s), 7.1-8.0(9H, m)I-327 oily 5.11(2H, s), 6.93(1H, s), 7.1-7.7(4H, complex) 7.17 (5H, s)I-574 47-50 2.37(3H, s), 5.08(2H, s), 6.24(1H, s), 7.07(2H, d, J = 8.9Hz), 7.15(5H, s), 7.44(2H, d, J = 8.9Hz)I-964 oily 4.6-4.9(2H, m), 5.0-5.5(2H, m), 5.16(2H, s) 5.5-6.2(1H, m), 5.77(1H, s), 7.20(5H, s), 7.2-7.6(4H, m)I-967 76-77 1.32(3H, t, J = 6.9Hz), 4.32(2H, q, J = 6.9Hz), 5.11(2H, s), 5.73(1H, s), 6.9-7.6(8H, m)I-1107 oily 2.27(3H, s), 3.89(3H, s), 5.14(2H, s), 5.76(1H, s), 6.8-7.6(8H, m)I-1195 oily 2.18(3H, s), 5.20(2H, s), 6.23(1H, s), 6.7-7.6(9H, m)I-1234 50-53 2.26(3H, s), 5.07(2H, s), 6.21(1H, s), 6.8-7.6(8H, m)I-1366 oily 1.28(3H, t, J = 6.9Hz), 4.30(2H, q, J = 6.9Hz), 5.24(2H, s), 5.70(1H, s), 6.9-7.5(8H, m)I-1494 oily 2.26(3H, s), 3.87(3H, s), 5.12(2H, s), 5.75(1H, s), 6.8-7.6(4H, m), 7.06(4H, s)I-1557 oily 3.68(3H, s), 3.86(3H, s), 5.07(2H, s), 5.73(1H, s), 6.68(2H, d, J = 8.5Hz), 7.10(2H, d, J = 8.5Hz), 7.0-7.6(4H, m)I-1561 55-57 1.31(3H, t, J = 6.9Hz), 4.30(2H, q, J = 6.9Hz), 5.08(2H, s), 5.71(1H, s), 7.0-7.6(8H, m)I-1623 oily 3.86(3H, s), 5.17(2H, s), 5.76(1H, s), 7.1-7.7(8H, m)I-1752 oily 3.87(3H, s), 5.09(2H, s), 5.76(1H, s), 7.0-7.6(8H, m)______________________________________
Reference Synthesis Example 1
Synthesis of 6-chloro-2-phenylmethoxy-4-(2-propenyloxy)-pyrimidine (Compound No. II-2)
Into a 50 ml eggplant type flask, 4,6-dichloro-2-(phenylmethoxy)pyrimidine (Compound No. II-26) (1.5 g, 5.9 mmol) and allyl alcohol (0.342 g, 5.9.times.1.0 mmol) were introduced, and dimethylformamide (20 ml) was added thereto to prepare a solution. While cooling with ice, 60% sodium hydride (0.247 g, 5.9.times.1.05 mmol) which had been washed with hexane was added. After stirred for overnight at room temperature, the reaction solution was poured into iced water and extracted with toluene (40 ml). The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate, and thereafter, the solvent was distilled off to obtain an oily product. The product was then purified on silica gel column chromatography (Wakogel C300, 300 ml, hexane/ethyl acetate=25/1000(v/v)) to obtain the end compound.
Yield: 0.7 g (42.9%).
Reference Synthesis Example 2
Synthesis of 4-chloro-6-(3-methyl-2-butenyloxy)-2-(phenylmethoxy)pyrimidine (Compound No. II-3)
(1) Synthesis of an intermediate, 4-chloro-6-(3-methyl-2-butenyloxy) -2-(methylsulfonyl) pyrimidine (Compound No. VIII-3)
Into a 100 ml eggplant type flask, 4-chloro-6-(3-methyl-2-butenyloxy) -2-(methylthio) pyrimidine (Compound No. VII-3) (2.45 g, 10.0 retool) was introduced, and dichloromethane (40 ml) was added thereto to prepare a solution. While cooling with ice, m-CPBA (3.45 g, 10.0.times.2.0 mmol) was added by small portions. An hour later, ice bath was removed, and the solution was then stirred for overnight at room temperature. Aqueous saturated sodium hydrogen carbonate was added to the reaction solution, and after shaking, an organic phase was separated. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate, and thereafter, the solvent was distilled off to obtain an oily product (2.5 g). The product was then purified on silica gel column chromatography (Wakogel C300, 300 ml, hexane/ethyl acetate=(300 ml/150 ml) to obtain the Compound No. VIII-3 from the fraction of 300 ml to 380 ml.
Yield: 0.7 g (25.3%). Oily product. .sup.1 H-NMR (60 MHz, CDCl.sub.3,.delta.): 1.77(6H,s), 3.30(3H,s), 4.9-5.1(2H,d,7 Hz), 5.3-5.6(1H,m), 6.90(1H,s). (2) Synthesis of the Compound No. II-3 from the intermediate
Into a 50 ml eggplant type flask, the intermediate obtained from the preceding section (1), Compound No. VIII-3 (0.50 g, 1.8 mmol) and benzyl alcohol (0.195 g, 1.8.times.1.0 mmol) were introduced, and DMF (10 ml) was added thereto to prepare a solution. While cooling with ice, 60% sodium hydride (79.5 mg, 1.8.times.1.1 mmol) which had been washed with hexane was added. After stirred for overnight at room temperature, the reaction solution was poured into iced water and extracted with toluene (20 ml). The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate, and thereafter, the solvent was distilled off to obtain an oily product (0.6 g). The product was then purified on silica gel column chromatography (Wakogel C300, 100 ml, hexane/ethyl acetate=300 ml/30 ml) to obtain the Compound No. II-3.
Yield: 0.3 g (54.7%). Purity: 91.9%. (Rt=10.7 min.: ODSF411A, acetonitrile/water=70/30(v/v), 1 ml/min., 250 nm). .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 1.70(6H,s), 4.75(2H,d,7 Hz), 5.2-5.5(1H,m), 5.33(2H,s), 6.27(1H,s), 7.1-7.5(5H,m).
Reference Synthesis Example 3
Synthesis of 4-chloro-6-methyl-2-(phenylmethoxy)pyrimidine (Compound No. II-4)
(1) Synthesis of an intermediate, 4-chloro-6-methyl-2-(methylsulfonyl)pyrimidine (Compound No. VIII-4)
4-Chloro-6-methyl-2-(methylthio)pyrimidine (2.0 g, 0.0114 mol) (Compound No. VII-4) was dissolved in chloroform, and m-CPBA (5.64 g (purity ca.70%), 0.0114.times.2.0 mol) was added thereto, and then the resulting solution was allowed to react for about 2 hours at room temperature. The reaction solution was partitioned between chloroform and aqueous saturated sodium hydrogen carbonate to separate an organic phase. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, thereafter the residue was purified on a silica gel column to obtain the Compound No. VIII-4.
Yield: 2.25 g (95%). Melting point: 67.degree.-70.degree. C. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 2.63(3H,s), 3.30(3H,s), 7.38 (1H,s).
(2) Synthesis of the Compound No. II-4 from the intermediate
In THF, an alkoxide was prepared from benzyl alcohol (1.65 g, 0.010.times.1.5 mol) and NaH (0.43 g, (ca. 60% in mineral oil), 0.010.times.1.05 mol). The Compound No. VIII-4 (2.10 g, 0.010 mol) obtained from the preceding section (1) was added thereto and allowed to react for 2 hours at room temperature. The reaction solution was partitioned between ethyl acetate and aqueous saturated sodium hydrogen carbonate to separate an organic phase. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, and thereafter the residue was purified on a silica gel column to obtain the title compound as an oily product.
Yield: 1.31 g (56%). .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 2.37(3H,s), 5.33(2H,s), 6.73(1H,s), 7.1-7.6(5H,m).
Reference Synthesis Example 4
Synthesis of 4-chloro-6-methoxy-2-(phenylmethoxy)pyrimidine (Compound No. II-7)
(1) Synthesis of an intermediate, 4-chloro-6-methoxy-2-(methylthio)pyrimidine (Compound No. VII-7)
4,6-Dichloro-2-(methylthio)pyrimidine (compound VII-23) (19.5 g, 0.100 mol) was dissolved in tetrahydrofuran (200 ml) which had just been distilled, and then methyl alcohol (3.2 g, 0.100.times.1.0 mol) was added thereto. Under cooling with ice, 60% sodium hydride (4.4 g, 0.100.times.1.1 mol) was added while stirring. After stirred for 3 hours, the reaction solution was poured into water, and extracted with toluene. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and filtered, and thereafter the solvent was distilled off to obtain the Compound No. VII-7.
Yield: 19.0 g. .sup.1 H-NMR (60 MHz, CDCl.sub.13, .delta.) 2.47(3H,s), 3.85(3H,s), 6.27 (1H,s).
(2) Synthesis of an immediately preceding intermediate, 4-chloro-6-methoxy-2-(methylsulfonyl)pyrimidine (Compound No. VIII-7)
The intermediate obtained from the preceding section (1), the Compound No. VII-7 (19.0 g, 0.100 mol) was dissolved in acetic acid (200 ml), and aqueous 31% hydrogen peroxide (25.2 g, 0.100.times.2.3 mol) was added thereto, and the mixture was heated to 100.degree. C. while stirring. After stirred for 2 hours, the reaction solution was poured into water and extracted with ethyl acetate. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, and thereafter the solvent was distilled off to obtain a crude product 20.0 g. The product was then purified on silica gel column chromatography (Wakogel C300, 300 ml, ethyl acetate/hexane=400 ml/400 ml) to obtain the Compound No. VIII-7 as a white crystal from the fraction of 300 ml to 600 ml.
Yield: 11.5 g. Melting point: 68.degree.-74.degree. C. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 3.30(3H,s), 4.07(3H,s), 6.87(1H,s)
(3) Synthesis of the Compound No. II-7 from the immediately preceding intermediate
4-Chloro-6-methoxy-2-(methylsulfonyl)pyrimidine (Compound No. VIII-7) (0.80 g, 0.0036 mol) and benzyl alcohol (0.39 g, 0.0036 mol) were dissolved in toluene (10 ml), and then 60% sodium hydride (0.16 g, 0.0036.times.1.1 mol) was added thereto while cooling with ice. After stirred for overnight at room temperature, the reaction solution was poured into water and extracted of ethyl acetate. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and filtered, thereafter the solvent was distilled off to obtain 0.92 g of a crude product. The product was then purified on silica gel column chromatography to obtain the Compound No. II-7 as an oily product.
Yield: 0.5 g. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 3.80(3H,s), 5.30(2H,s), 6.20(1H,s), 7.1-7.5(5H,m)
Reference Synthesis Example 5
Synthesis of 4-chloro-6-ethylthio-2-(phenylmethoxy)-pyrimidine (Compound No. II-16)
Ethane thiol (0.366 g, 0.0059.times.1.0 mol) was dissolved in THF, and then NaH (0.24 g, (ca.60% in mineral oil), 0.0059.times.1.0 mol) was added thereto. The resulting solution was added dropwise to 4,6-dichloro-2-(phenylmethoxy)pyrimidine (Compound No. II-26) (1.5 g, 0.0059 mol) dissolved in THF and then stirred for about 3 hours at room temperature.
In order to completely remove the unreacted starting material (Compound No. II-26), 40% aqueous methylamine (0.23 g, 0.0059.times.0.5 mol) was added and stirred for about 1 hour at room temperature. The reaction solution was poured into water and extracted with ethyl acetate to separate an organic phase. The organic phase was washed with aqueous saturated sodium chloride, dried and concentrated, thereafter purified on a silica gel column to obtain the Compound No. II-16.
Yield: 1.55 g (94%). Melting point: 55.degree.-57.degree. C. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.) 1.30(3H, t,J=6.9 Hz), 3.08(2H, q,J=6.9 Hz), 5.34(2H,s), 6.70(1H,s), 7.0-7.6(5H,m).
Reference Synthesis Example 6
Synthesis of 4,6-dibromo-2-(phenylmethoxy)pyrimidine (Compound No. II-25)
(1) Synthesis of an intermediate, 4,6-dibromo-2-(methylthio)pyrimidine (Compound No. VII-22)
Into a 300 ml eggplant type flask, 4,6-dihydroxy-2-(methylthio)pyrimidine (12.5 g, 0.079 mol) and phosphoryl tribromide (49.8 g, 0.079.times.2.1 mol) were introduced and the flask was immersed in an 80.degree. C. oil bath, and the mixture was then stirred for 30 minutes. The reaction mixture was allowed to cool to room temperature and dissolved in ethyl acetate, and then poured onto ice to separate an organic phase. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and filtered, and thereafter the solvent was distilled off. The residue was purified on silica gel column chromatography (Wakogel C300, 300 ml, ethyl acetate/hexane=35 ml/700 ml) to obtain a white crystal from the fraction of 120 ml to 480 ml.
Yield: 14.6 g. Melting point: 90.degree.-92.degree. C.
(2) Synthesis of an immediately preceding intermediate, 4,6-dibromo-2-(methylsulfonyl)pyrimidine (Compound No. VIII-22)
Into a 100 ml eggplant type flask, the intermediate obtained from the preceding section (1), the Compound No. VII-22 (5.7 g, 20.1 mmol) was introduced, then dissolved in acetic acid (50 ml), and aqueous 31% hydrogen peroxide (4.5 g, 20.1.times.2.1 mmol) was added thereto and the mixture was allowed to react at 100.degree. C. for 3 hours.
Since HPLC monitoring showed that 13.2% of the starting material was remained (Rt=5.1 min., acetonitrite/water=70/30 (v/v), 1 ml/min., 250 nm), aqueous 31% hydrogen peroxide (1.0 g, 20.1.times.0.47 mmol) was further added thereto and the mixture was allowed to react for another 1 hour. After allowed to cool to room temperature, the reaction solution was poured into iced water and extracted with toluene. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate, and thereafter the solvent was distilled off to obtain the Compound No. VIII-22 as a white crystal.
Yield: 4.5 g (72.5%). Purity: 97.5%. (Rt=2.3 min.: ODS411A, acetonitrile/water =70/30, 1 ml/min., 250 nm) Melting point: 12120.degree.-124.degree. C.
(3) Synthesis of the Compound No. II-25 from the immediately preceding intermediate
4,6-Dibromo-2-(methylsulfonyl)pyrimidine (Compound No. VIII-22) (1.5 g, 0.00476 mol) was dissolved in toluene, and then benzyl alcohol (0.515 g, 0.00476.times.1.0 mol) was added thereto. Under cooling with ice, 60% sodium hydride (0.21 g, 0.00476.times.1.1 mol) was added while stirring. After stirred for 6 hours, the reaction solution was poured into water and extracted with toluene. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and filtered, and thereafter the solvent was distilled off. The residue was purified on silica gel column chromatography (Wakogel C300, 100 ml, ethyl acetate/hexane=20 ml/400 ml) to obtain the Compound No. II-25 as an oily product from the fraction of 100 ml to 120 ml.
Yield: 0.5 g. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 5.20(2H,s), 7.10(1H,s), 7.1-7.8(5H,m)
Reference Synthesis Example 7
Synthesis of 4,6-dichloro-2-(phenylmethoxy)pyrimidine (Compound No. II-26)
Into a 500 ml eggplant type flask, 4,6-dichloro-2-(methylsulfonyl)pyrimidine (Compound No. VIII-23) (21.3 g, 93.8 mmol) and benzyl alcohol (10.1 g, 93.8.times.1.0 mmol) were introduced, and dimethylformamide (150 ml) was added thereto to prepare a solution. While stirring in ice bath, 60% sodium hydride (3.94 g, 93.8.times.1.05 mmol) which had been washed with hexane was added. After bubbling ceased, ice bath was removed and the reaction solution was stirred for 2 hours at room temperature. The reaction mixture was poured onto ice and the separated organic matter was extracted with ethyl acetate. The organic phase was washed successively with diluted hydrochloric acid and aqueous saturated sodium chloride, dried over anhydrous sodium sulfate, and thereafter the solvent was distilled off. The residue was purified on silica gel column chromatography (Wakogel C300, ethyl acetate/hexane=1/50) to obtain the Compound No. II-26.
Yield: 6.5 g (27%). Oily product.
Reference Synthesis Example 8
Synthesis of 4-methyl-2-methylsulfonyl-6-phenoxypyrimidine (Compound No. V-4)
(1) Synthesis of an intermediate, 4-methyl-2-methylthio-6-phenoxypyrimidine
Phenol (1.72 g, 11.5.times.1.50 mmol) was dissolved in THF, and 60% sodium hydride (0.69 g, 11.5.times.1.50 mmol) was added thereto to prepare a phenoxide. 4-Chloro-6-methyl-2-(methylthio)pyrimidine (Compound No. VII-4) (2.0 g, 11.5 mmol) was added thereto and the mixture was refluxed for about 8 hours.
The reaction solution was poured into water and extracted with ethyl acetate. The organic phase was washed successively with diluted hydrochloric acid and aqueous saturated sodium chloride, then dried over anhydrous sodium sulfate and concentrated, thereafter purified on a silica gel column to obtain the intermediate.
Yield 1.49 g (56%). Oily product. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 2.34(6H,s), 6.21(1H,s), 6,8-7.6 (5H,m). IR (liq., cm.sup.-1): 2936, 1576, 1496, 1442, 1386, 1358, 1280, 1200, 1168, 1070, 1024, 994, 964, 922, 834, 768, 696.
(2) Synthesis of the Compound No. V-4 from the intermediate
4-Methyl-2-methylthio-6-phenoxypyrimidine (1.40 g, 0.0060 mol) was dissolved in chloroform, and then m-CPBA (3.12 g, 6.0.times.2.1 mmol) was added thereto. The resulting solution was allowed to react for 2 hours at room temperature. The reaction solution was concentrated and thereafter purified on a silica gel column.
Yield: 1.20 g (75%). .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.) 2.56(3H,s), 3.12(3H,s), 6.76(1H,s), 6.8-7.7(5H,m). IR (liq., cm.sup.-1): 3032, 2940, 2368, 1738, 1584, 1542, 1494, 1446, 1392, 1368, 1322, 1206, 1144, 1072, 1026, 966, 912, 864, 816, 754, 698.
Reference Synthesis Example 9
Synthesis of 2-methylsulfonyl-4-�3-(trifluoromethyl)-phenoxy!pyrimidine (Compound No. V-232)
(1) Synthesis of an intermediate, 2-methylthio-4-�3-(trifluoromethyl)phenoxy!pyrimidine
In THF, a phenoxide was prepared from 3-(trifluoromethyl)phenol (4.54 g, 0.0187.times.1.5 mol) was mixed with NaH (1.12 g (ca. 60% in mineral oil), 0.0187.times.1.5 mol), and 4-chloro-2-(methylthio)pyrimidine (Compound No. VII-1) (3.0 g, 0.0187 mol) was added thereto and the mixture was refluxed for about 10 hours. The reaction solution was partitioned between ethyl acetate and aqueous saturated sodium hydrogen carbonate to separate an organic phase. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, then recrystallized from a methanol/water system to obtain the intermediate compound.
Yield: 2.85 g (53%). .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 2.28(3H,s), 6.47(1H,d,J=5.5 Hz), 7.0-7.6(4H,m), 8.27(1H,d,J=5.5 Hz)
(2) Synthesis of the Compound No. V-232 from the intermediate 2-Methylthio-4-�3-(trifluoromethyl)phenoxy!pyrimidine (2.65 g, 0.00926 mol) was dissolved in chloroform, and then m-CPBA (4.79 g (purity ca.70%), 0.00926.times.2.1 mol) was added thereto. The resulting solution was allowed to react for about 2 hours at room temperature. The reaction solution was partitioned between chloroform and aqueous saturated sodium hydrogen carbonate to separate an organic phase. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, and thereafter purified on a silica gel column to obtain the Compound No. V-232.
Yield: 2.17 g (74%). Melting point: 117.degree.-121.degree. C. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 3.08(3H,s), 7.08(1H,d, J=5.5 Hz), 7.2-7.8(4H,m), 8.71(1H,d, J=5.5 Hz)
Reference Synthesis Example 10
Synthesis of 4-ethoxy-2-methylsulfonyl-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. V-242)
(1) Synthesis of an intermediate, 4-ethoxy-2-methylthio-6-�3-(trifluoromethyl)phenoxy!pyrimidine
Ethanol (1.18 g, 0.0256.times.1.0 mol) and NaH (1.02 g, (ca.60% in mineral oil), 0.0256.times.1.0 mol) were dissolved in THF and 4,6-dichloro-2-methylthiopyrimidine (Compound No. VII-23)(5.0 g, 0.0256 mol) was added thereto. The resulting solution was stirred for about 30 minutes at room temperature. To this reaction solution, m-trifluoromethyl-phenol (6.23 g, 0.0256.times.1.5 mol), NaH (1.54 g, (ca.60% in mineral oil), 0.0256.times.1.5 mol), and KI (2.12 g, 0.0256.times.0.5 mol) dissolved in DMF were added. The resulting solution was refluxed for about 7 hours. The reaction solution was partitioned between ethyl acetate and aqueous saturated sodium hydrogen carbonate to separate an organic phase. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, and thereafter purified on a silica gel column.
Yield: 6.66 g (79%). Oily product. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 1.32(3H, t,J=6.9 Hz), 2.28(3H, S), 4.30(2H, q,J=6.9 Hz), 5.68(1H,s), 7.4-7.6(4H,m).
(2) Synthesis of the Compound No. V-242 from the intermediate
4-Ethoxy-2-methylthio-6-�3-(trifluoromethyl)phenoxy!-pyrimidine (6.56 g, 0.020 mol) was dissolved in chloroform, and m-CPBA (3.16 g (purity ca.70%), 0.020.times.2.0 mol) was added thereto. The resulting solution was allowed to react for about 2 hours and 30 minutes at room temperature. The reaction solution was partitioned between chloroform and aqueous saturated sodium hydrogen carbonate to separate an organic phase. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, and thereafter purified on a silica gel column to obtain the Compound No. V-242.
Yield: 6.60 g (92%). Melting point: 114.degree.-116.degree. C. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 1.37(3H, t,J=6.9 Hz), 3.07(3H,s), 4.46(2H, q,J=6.9 Hz), 6.20(1H,s), 7.0-7.6(4H,m).
Reference Synthesis Example 11
Synthesis of 2-methylsulfonyl-4-trifluoromethyl-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. V-251)
(1) Synthesis of an intermediate, 2-methylthio-4-trifluoromethyl-6-�3-(trifluoromethyl)phenoxy!pyrimidine
m-(Trifluoromethyl)phenol (1.06 g, 0.0044.times.1.5 mol) and NaH (0.26 g (ca.60% in mineral oil), 0.0044.times.1.5 mol) were dissolved in THF, and then 4-chloro-2-methylthio-6-(trifluoromethyl)pyrimidine (Compound No. VII-17) (1.0 g, 0.0044 mol) was added thereto. The resulting solution was refluxed for about 7 hours. The reaction solution was partitioned between ethyl acetate and aqueous saturated sodium hydrogen carbonate to separate an organic phase. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated. Thereafter, remaining phenol and others were distilled off in a tubular oven (under water flow, 150.degree. C.) to obtain the intermediate compound.
Yield: 1.40 g (90%). Melting point: 39.degree.-41.degree. C. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 2.31(3H,s), 6.66(1H,s), 7.1-7.6 (4H,m).
(2) Synthesis of the Compound No. V-251 from the intermediate
The Compound No. V-251 was obtained in a similar manner to that described in the section (2) of Reference synthesis example 9, by starting from 2-methylthio-4-trifluoromethyl-6-�3-trifluoromethyl)phenoxy!pyrimidine (1.3 g, 0. 0037 mol).
Yield: 1.31 g (92%). Melting point: 119.degree.-123.degree. C. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 3.17(3H,s), 7.1-7.7(5H,m).
Reference Synthesis Example 12
Synthesis of 4-bromo-2-methylsulfonyl-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. V-253)
(1) Synthesis of an intermediate, 4-bromo-2-methylthio-6-�3-(trifluoromethyl)phenoxy!pyrimidine
In THF, a phenoxide was prepared from m-(trifluoromethyl)phenol (1.30 g, 0.00794.times.1.0 mol) and NaH (0.32 g (ca. 60% in mineral oil), 0.00794.times.1.0 mol), and 4,6-dibromo-2-(methylthio)pyrimidine (Compound No. VII-22) (2.0 g, 0.00794 mol) was added thereto, and the mixture was then allowed to react for 5 hours at room temperature.
The reaction solution was partitioned between ethyl acetate and aqueous saturated sodium hydrogen carbonate to separate an organic phase. The organic phase was then washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, thereafter purified on a silica gel column to obtain the end product.
Yield: 2.35 g (81%). Melting point: 70.degree.-71.degree. C. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 2.26(3H,s), 6.67(1H,s), 7.0-7.6 (4H,m).
(2) Synthesis of the Compound No. V-253 from the intermediate
4-Bromo-2-methylthio-6-�3-(trifluoromethyl)phenoxy!-pyrimidine (2.25 g, 0.00616 mol) was dissolved in chloroform, and m-CPBA (3.19 g (purity ca.70%), 0.00616.times.2.1 mol) was added thereto. The resulting solution was allowed to react for about 2 hours at room temperature. The reaction solution was partitioned between chloroform and aqueous saturated sodium hydrogen carbonate to separate an organic phase. The organic phase was then washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, and thereafter purified on a silica gel column.
Yield: 2.13 g (87%). Melting point: 95.degree.-97.degree. C. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 3.12(3H,s), 7.23(1H,s), 7.0-7.7 (4H,m).
Reference Synthesis Example 13
Synthesis of 4-chloro-2-methylsulfonyl-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. V-254)
(1) Synthesis of an intermediate, 4-chloro-2-methylthio-6-�3-(trifluoromethyl) phenoxy!pyrimidine
In THF, a phenoxy was prepared from m-(trifluoromethyl)phenol (2.5 g, 0.00154.times.1.0 mol) and Nail (ca.0.61 g (60% in mineral oil), 0.00154.times.1.0 mol).
4, 6-Dichloro-2-(methylthio)pyrimidine (Compound No. VII-23) (3.0 g, 0.0154 mol) was added thereto, and the mixture was then allowed to react for 5 hours at room temperature, and thereafter refluxed for about another 30 minutes. The reaction solution was partitioned between ethyl acetate and aqueous saturated sodium hydrogen carbonate to separate an organic phase. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, then recrystallized from a methanol/water system.
Yield: 3.56 g (72%). Melting point: 70.degree.-72.degree. C. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 2.29(3H,s), 6.51(1H,s), 7.1-7.6 (4H,m).
(2) Synthesis of the Compound No. V-254 from the intermediate
The Compound No. V-254 was synthesized in a similar manner to that described in the section (2) of Reference synthesis example 9, by starting from 4-chloro-2-methylthio-6-�3-(trifluoromethyl) phenoxy!pyrimidine (3.4 g, 0.0106 mol).
Yield: 3.48 g (93%). Melting point: 88.degree.-90.degree. C. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 3.12(3H,s), 7.06(1H,s), 7.1-7.7 (4H,m).
Reference Synthesis Example 14
Synthesis of 4-iodo-2-methylsulfonyl-6-�3-(trifluoromethyl)phenoxy!pyrimidine (Compound No. V-235)
(1) Synthesis of an intermediate, 4-iodo-2-methylthio-6-�3-(trifluoromethylphenoxy)!pyrimidine
To a THF solution containing m-(trifluoromethyl)phenol (1.0 g, 0.00661.times.1.0 mol) and NaH (0.24 g (ca. 60% in mineral oil), 0.00661.times.1.0 mol), 4,6-diiodo-2-(methylthio)pyrimidine (Compound No. VII-24) (2.5 g, 0.00661 mol) was added, and the mixture was then allowed to react for about 3 hours. The reaction solution was partitioned between ethyl acetate and aqueous saturated sodium hydrogen carbonate to separate an organic phase. The organic phase was washed with aqueous saturated sodium chloride, then dried over anhydrous sodium sulfate and concentrated, and thereafter purified on a silica gel column to obtain the end product.
Yield: 1.59 g (58%). Melting point: 73.degree.-75.degree. C. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 2.24(3H,s), 6.93(1H,s), 7.0-7.6 (4H, complex).
(2) Synthesis of the Compound No. V-255 from the intermediate
4-Iodo-2-methylthio-6-�3-(trifluoromethyl)phenoxy!-pyrimidine (1.49 g, 0.00362 mol) was dissolved in chloroform, and m-CPBA (1.87 g (purity ca.70%), 0.00362.times.2.1 mol) was added thereto. The resulting solution was allowed to react for about 3 hours at room temperature. The reaction solution was partitioned between chloroform and aqueous saturated sodium hydrogen carbonate. The organic phase was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated, thereafter purified on a silica gel column to obtain the Compound No. V-252.
Yield: 0.90 g (56%). Melting point: 102.degree.-106.degree. C. .sup.1 H-NMR (60 MHz, CDCl.sub.3, .delta.): 3.11(3H,s), 7.0-7.8(5H, complex).
Formulation examples and test examples are hereinafter described. Kinds of carriers (diluents) and additives to be used, as well as mixing ratios thereof and active ingredient contents therein may be modified in a broad range.
In each of the formulation examples, the term "parts" is "parts by weight" if otherwise noted.
Formulation Example 1 (wettable powder)
______________________________________Compound No. I-301 50 partsLignin sulfonate 5 partsAlkyl sulfonate 3 partsDiatomaceous earth 42 parts______________________________________
The above ingredients were mixed together and ground finely to form a wettable powder. It may be applied after diluted with water.
Formulation Example 2 (emulsifiable concentrate)
______________________________________Compound No. I-327 25 partsXylene 65 partsPolyoxyethylene alkylaryl ether 10 parts______________________________________
The above ingredients were homogeneously mixed to form an emulsifiable concentrate. It may be applied after diluted with water.
Formulation Example 3 (granules)
______________________________________Compound No. I-1234 8 partsBentonite 40 partsClay 45 partsLignin sulfonate 7 parts______________________________________
The above ingredients were homogeneously mixed, blended with water and processed into a granular form by means of an extrusion granulator to give granules.
Test Example 1 (Weed control test by foliage treatment)
Wettable powders were prepared as described in the Formulation example 1 and diluted to a predetermined concentration. Each of the formulated test compounds was applied at an active ingredient rate of 1000 g/ha onto the foliage of each plant grown to the 1 to 2 leaf stage. The tested plants were pot-cultivated redroot pigweed (Amaranthus retroflexus), wild mustard (Sinapis arvensis), sicklepod (Cassia obtusifolia), black nightshade (Solanum nigrum), velvet-leaf (Abutlion theophrasti), cleavers (Galium aparine), and ivyleaf speedwell (Veronica hederaefolia).
On the 14th day after the application, weed control effects were evaluated by the following criterion. Evaluation rating:
1: less than 30%;
2: 30% to less than 70%;
3: 70% or more.
The results are shown in Table 7.
TABLE 7______________________________________No. g/ha AR SA CO SN AT GA VH______________________________________I-4 1000 3 3 2 3 1 1 2I-214 1000 2 3 3 2 2 1 2I-301 1000 3 3 3 3 2 3 3I-302 1000 2 1 1 1 1 1 1I-304 1000 3 3 3 3 3 3 3I-307 1000 3 3 3 3 3 3 3I-311 1000 2 3 3 2 1 2 2I-315 1000 3 2 3 3 2 3 3I-316 1000 2 3 3 2 2 2 3I-322 1000 2 3 3 1 2 3 3I-325 1000 3 2 3 3 2 3 3I-326 1000 3 3 3 3 3 3 3I-327 1000 3 2 3 3 3 3 3I-574 1000 2 1 2 3 2 2 3I-964 1000 1 1 1 1 1 1 1I-967 1000 1 2 1 2 2 3 2I-1107 1000 2 2 3 2 2 3 3I-1195 1000 3 3 3 3 3 3 3I-1234 1000 3 3 3 3 3 3 3I-1366 1000 2 1 1 2 2 3 2I-1494 1000 2 2 1 2 2 1 2I-1557 1000 3 2 3 2 2 1 2I-1561 1000 2 3 3 2 2 1 2I-1623 1000 3 2 3 2 2 3 2I-1752 1000 3 3 3 3 2 3 3______________________________________ AR: Amaranthus retroflexus SA: Sinapis arvensis CO: Cassia obtusifolia SN: Solanum nigrum AT: Abutilon theophrasti GA: Galium aparine VH: Veronica hederaefolia
Test Example 2 (Germination test)
In a 9 cm diameter Petri dish having the bottom covered with double sheets of filter paper, 6 ml of aqueous suspension of a test compound (containing 50 ppm of active ingredient) was poured and ten seeds of each weed were placed. The tested weeds were redroot pigweed (Amaranthus retroflexus), black nightshade (Solanum nigrum), wild chamomile (Matricaria chamomilla), Green foxtail (Setaria viridis), and rice flatsedge (Cyperus iria).
The seeds was allowed to germinate in a constant-temperature chamber at 28.degree. C., and on the 14th day after the sowing, the inhibition of germination and the retarding of growth were visually observed and evaluated by the following 3-grade criterion. Evaluation rating:
1: less than 30%;
2: 30% to less than 70%;
3: 70% or more.
The results are shown in Table 8.
TABLE 8______________________________________No. ppm AR SN MC SV CI______________________________________I-4 50 3 2 1 1 1I-214 50 2 3 1 2 1I-301 50 3 3 2 3 3I-302 50 1 1 1 1 1I-304 50 3 2 3 3 3I-307 50 3 1 1 3 3I-311 50 2 3 2 1 2I-315 50 3 3 2 2 3I-316 50 2 3 2 3 2I-322 50 2 3 2 3 2I-325 50 3 2 3 3 2I-326 50 3 1 1 3 3I-327 50 2 3 3 2 2I-574 50 2 2 1 2 1I-964 50 1 1 1 1 1I-967 50 3 2 3 1 2I-1107 50 2 3 2 2 1I-1195 50 2 1 1 3 2I-1234 50 2 1 1 1 2I-1366 50 2 1 1 2 2I-1494 50 2 1 2 2 1I-1557 50 3 1 2 1 2I-1561 50 2 3 1 2 2I-1623 50 1 2 2 1 2I-1752 50 3 1 1 3 3______________________________________ AR: Amaranthus retroflexus SN: Solanum nigrum MC: Matricaria chamomilla SV: Setaria viridis CI: Cyperus iria

Number	Date	Country
2113216	Aug 1983	GBX
2 285 045	May 1995	GBX

2-benzyloxy-4-phenoxypyrimidine derivative, processes for producing the derivative and herbicidal composition containing the derivative

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

Priority Claims (1)

US Referenced Citations (1)

Foreign Referenced Citations (2)

Non-Patent Literature Citations (4)

Entry
J. Chem. Soc. 1965, 5542-5551, "The Dimroth Rearrangement. Part IV" by Brown et al.
J. Chem. Soc. 1975, 1798-1802, "Unconventional Nucleotide Analogues. Part XIV" by Kaspersen et al.
J. Chem. Soc. 1959, 525-530, "Pyrimidines, Part X" by Hunt et al.
Agr. Biol. Chem. vol. 30, No. 9, pp.896-905, 1966, "Synthesis and Herbicidal Activities of Phenoxypyrimidines and Phenoxytriazines" by Jojima et al.